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Gammaherpesviruses are oncogenic viruses that establish latent infection and can 
periodically reactivate. Replication, reactivation from latency and gammaherpesvirus-mediated 
pathology are regulated by viral and host factors. Long-standing interests in the field include 
understanding viral gene expression and regulation during lytic and latent infection and the 
effects of chronic viral infection on the host. Murine gammaherpesvirus 68 (MHV68) is used to 
model features of human gammaherpesvirus biology. 
In this dissertation, I investigated: (1) the function of antisense viral transcripts; (2) Stat1 
regulation of MHV68 gene 50 promoters; and (3) the effect of chronic infection on host gene 
expression. Our laboratory identified extensive transcription outside of annotated open reading 
frames (ORFs) in the MHV68 genome, which we termed expressed genomic regions (EGRs). 
Similar pervasive transcription is also observed in the related human gammaherpesvirus, 
Kaposi's sarcoma-associated herpesvirus (KSHV). Despite their prevalence, the functions of 
these novel transcripts are largely unknown. To study their function in MHV68 gene expression, 
we targeted thirteen EGRs using strand-specific antisense oligonucleotides and found targeting 
of six EGRs reduced late viral gene expression. We identified three transcripts enriched in the 
nucleus of infected cells, the first putative nuclear noncoding RNA to be identified in MHV68. 
xiv 
 
ORF50, the latent-to-lytic switch gene in MHV68 and KSHV, is sufficient to induce lytic 
reactivation from latently infected cells. We determined that interferon-gamma (IFNγ), which 
controls viral reactivation of MHV68, suppressed ORF50 transcription by regulating its 
promoters in a Stat1-dependent manner, suggesting that the virus maintains Stat1-responsive 
elements to control the viral life cycle. 
To assess the effect of chronic viral infection on host gene expression, we analyzed the 
transcriptional profile of tissues from latently infected mice and identified over 600 differentially 
expressed genes. We identified organ-specific transcriptional changes in gene expression. Most 
differentially expressed genes were involved in immune signaling, immune response, or cell 
cycle pathways and many were associated with IFNγ signaling. 
Taken together, these studies provide the first functional evidence for the importance of 
regions of pervasive transcription in MHV68 and add to our understanding of how the cytokine, 
IFNγ, controls viral infection and may modulate gene transcription in the host. 
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Chapter 1: 
Introduction 
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1.1 Herpesviridae Family and Viral Life Cycle 
The Herpesviridae family consists of three subfamilies, Alpha-, Beta-, and 
Gammaherpesvirinae, which share common virion architecture and large double-stranded DNA 
genomes and are able to establish lifelong latency in their hosts (96). During productive 
infection, herpesviruses replicate in the nucleus; release of progeny virus occurs with destruction 
of the infected cell. There is an initial production of virus during acute infection of a naïve host. 
The immune system is unable to completely clear herpesvirus infection, resulting in chronic 
infection. There are three components of chronic herpesvirus infections: (1) latent infection, (2) 
reactivation from latency and (3) persistent infection (134). Latency is characterized 
experimentally as the presence of viral genome without preformed infectious virus. Latent virus 
retains the capacity to resume production of infectious virus and return to the lytic viral life 
cycle. The emergence of virus from latently infected cells is termed reactivation. Persistent 
infection is the production of infectious virus during chronic infection and can result from either 
continuous replication or reactivation from latency (134). 
 Herpesviruses have co-evolved with their hosts and exhibit restricted host range (80, 96). 
Following entry into host cells, viral particles enter the nucleus where viral replication and virion 
assembly occur. Viral genes are expressed in a regulated fashion; immediate-early genes require 
no viral protein synthesis for expression; early genes are independent of viral DNA synthesis, but 
require new viral protein synthesis; and late genes require viral DNA synthesis and are often 
structural. Release of infectious progeny virus causes destruction of the infected cell (96, 97). 
Most genes are expressed during lytic replication whereas only a restricted set of transcripts is 
produced during latent infection (44). 
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 The gammaherpesviruses are characterized by their limited host range and ability to 
establish latency in immune cells (96). Epstein-Barr Virus (EBV, HHV-4) and Kaposi's sarcoma-
associated herpesviruses (KSHV, HHV-8) are the human gammaherpesviruses. EBV and KSHV 
are oncogenic and are associated with lymphomas, carcinomas and Kaposi's sarcoma in infected 
individuals. Although many cases of EBV infection are clinically asymptomatic, acute EBV 
infection is one of the causes of infectious mononucleosis (23, 114). EBV is also associated with 
Burkitt's lymphoma, post-transplant lymphoproliferative disease, nasopharyngeal carcinoma, 
Hodgkin's lymphoma, and gastric adenocarcinoma (50, 52, 55). KSHV was first identified using 
representational difference analysis of Kaposi's sarcoma lesions from patients with AIDS in 
comparison to normal tissue (16) and is strongly implicated as required for the development of 
Kaposi's sarcoma (44, 83). Interestingly, a role for lytic replication in Kaposi's sarcoma 
tumorigenesis has been suggested (49). KSHV is also linked to HIV-associated multicentric 
Castleman's disease and primary effusion lymphoma (8, 87). The association of KSHV and EBV 
with a variety of cancers in immunosuppressed patients suggests an important role for immune 
regulation in control of pathologies caused by these viral infections. 
 
1.1.1 Murine Gammaherpesvirus 68 Model System 
 Murine gammaherpesvirus 68 (MHV68, γHV-68, MuHV4) is genetically related to the 
human gammaherpesviruses, KSHV and EBV (36, 37, 116, 135). Infection with KSHV and EBV 
is species specific and de novo infection in vitro has a proclivity for latent infection, limiting the 
ability of investigators to study the dynamics of productive infection (44, 66). MHV68 provides 
a tractable small animal model system to investigate features of gammaherpesvirus pathogenesis 
in vivo and productive primary infection in vitro (36, 37, 116, 135). During productive infection 
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of fibroblasts and replication during acute infection of mice, all known ORFs are detectably 
expressed (62, 78, 103). During latent infection, a restricted set of transcripts is expressed, 
including mK3, ORFs 73 and 74 (latency-associated nuclear antigen, LANA, and viral G-protein 
coupled receptor homolog, GPCR, respectively) and many of the MHV68-specific genes, such as 
M2, M3, M8, M9 and M11 (viral Bcl-2) (78, 103, 136). 
 
1.1.2 In vivo infection and pathogenesis 
MHV68 infects multiple cell types in vivo during acute infection and establishes latent 
infection in macrophages, dendritic cells and B cells (38-41, 67, 124, 125, 140). It causes 
lymphoproliferative disease, splenic and pulmonary fibrosis and large-vessel vasculitis in 
immunocompromised mice (33-35, 74, 126, 127, 129, 139). The development of these 
pathologies in mice requires the presence of persistent virus (25, 86). 
Numerous viral genes have been identified as playing a role in establishment of, or 
reactivation from, latency, including viral-cyclin (ORF 72), viral-GPCR (ORF 74), viral-bcl-2 
(M11), and the LANA homolog (ORF 73) (28, 43, 45, 84, 85, 92, 133). While most viral genes 
that have been examined to date are important for promoting latency or the development of 
disease, M1 is reported to suppress reactivation and the development of atypical lymphoid 
hyperplasia (19, 127). 
 
1.1.3 Pervasive Transcription of MHV68 
In vitro, MHV68 can infect multiple cell types including fibroblasts, macrophages, and 
endothelial cells. Lytic replication is typically studied in vitro in fibroblast cell lines which are 
highly permissive for infection. The complete sequence of the 119,450 base pair genome of 
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MHV68 was originally reported to contain at least 80 open reading frames (ORFs) defined as 
methionine-initiated ORFs of at least 100 amino acids (135). Such an annotation, however, fails 
to identify noncoding RNAs, spliced exons and small protein-coding genes (62). Indeed, 
subsequent studies have identified splice forms of several ORFs (2, 29, 48). Moreover, a tiled 
array designed in our laboratory reveals that many regions of the MHV68 genome that do not 
correspond to annotated ORFs are actively transcribed during productive infection in fibroblasts 
at 18 hours post-infection (62). We identified over 73,000 nucleotides of unexpected 
transcription, representing a 31% increase in the RNA coding potential of this virus. The 
presence of pervasive transcription of MHV68 has also been confirmed by others (17). We 
termed regions of unexpected transcription as Expressed Genomic Regions (EGRs) when RNA 
expression is: (1) at least 700 nucleotides 5’ or 3’ of an annotated ORF or, if not associated with 
an annotated ORF, at least 700 nucleotides in length, (2) greater than one standard deviation 
above the mean signal from mock-infected cells, and (3) detectable at each nucleotide in at least 
two of three independent experiments. Using these criteria, 30 EGRs are expressed in fibroblast 
cells. MHV68 EGRs range in size from about 700 nucleotides to nearly 10,000 nucleotides and 
can encode multiple transcripts (62). 
This same phenomenon of extensive antisense transcription has recently been described 
in the human gammaherpesvirus, KSHV, and has also been recognized in the betaherpesvirus, 
human cytomegalovirus (HCMV) (14, 147). The functional significance of this pervasive 
transcription is one area of focus in this dissertation. By comparing ORFs greater than 20 amino 
acids in all possible reading frames of MHV68, KSHV, EBV and Herpesvirus saimiri, Johnson 
et al. identified gammaherpesvirus conserved putative peptide sequences in eight of 30 (27%) 
EGRs. These conserved regions are small (less than 60 amino acids on average) and are limited 
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to regions of EGRs where the protein-coding ORF on the opposite strand is also highly 
conserved, suggesting that the conservation noted may be due to sequence constraints of the 
opposite strand ORFs (62). In addition, unannotated ORFs greater than 20 amino acids were 
compared to the GenBank database. However, none of these sequences are conserved with 
sequences for annotated peptides or proteins currently available in GenBank (Dr. L. Steven 
Johnson, personal communication). Therefore, we hypothesized that few of the EGRs encode 
proteins and propose that a substantial portion of these newly identified transcripts may be 
noncoding RNAs (ncRNAs). Further characterization and functional analyses of EGR-encoded 
transcripts is presented in Chapter 2. Examples of known ncRNA function from other 
herpesviruses will be presented at the end of this Chapter. 
 
1.1.4 ORF 50: The Molecular Latent-to-Lytic Switch 
MHV68 open reading frame 50 (ORF 50), an immediate-early gene that encodes the 
replication and transcription activator (RTA), is the latent-to-lytic switch gene, a feature that is 
shared by all gammaherpesvirus RTAs (118). ORF 50 is both necessary and sufficient to induce 
lytic reactivation in latently infected cells (76, 93, 94, 118, 143). ORF 50 induces lytic 
reactivation through the transactivation of other viral promoters (26, 93, 118, 143). Since 
gammaherpesvirus transmission and disease often occur following reactivation from latency, 
understanding ORF 50 regulation is important to understanding disease pathogenesis (66). When 
ORF 50 is constitutively expressed (as driven by the MCMV IE1 promoter), the virus is unable 
to establish latency (79), suggesting that elements within the ORF 50 promoter may be important 
in regulating the transition between latent and lytic infection. Several negative regulators of 
KSHV ORF 50 have been previously identified, including the transcription factors, NF-κB and 
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RBP-Jκ and the viral gene, LANA (ORF73) (9, 61, 69, 70). NF-κB is also known to inhibit 
MHV68 lytic replication (9). We determined that interferon-gamma (IFNγ) suppresses ORF 50 
transcript expression in bone marrow derived macrophages (47), suggesting that IFNγ may 
regulate the transition between lytic replication and latency by suppressing RTA expression 
(Chapter 3). 
 
1.1.5 Role of Interferons in MHV68 Infection 
 Interferons (IFNs) were first described for their ability to interfere with viral infection 
(58). In MHV68, both type I and type II IFNs play important, but distinct, roles in controlling 
viral infection. Type I IFNs are critically important to controlling replication during acute 
infection; mice unresponsive to IFNα/β succumb to dose-dependent mortality after infection 
(32). Although type II IFN is typically unnecessary for control of replication during the early 
stages of MHV68 infection, a recent study identified a role for IFNγ responsiveness in the 
BALB/c background to protect mice from acute bronchopneumonia (73, 112, 139). 
Both type I and type II IFNs regulate reactivation of MHV68 from latency; ex vivo 
reactivation frequency is increased in IFNα/βR-, IFNγ-, and IFNγR-deficient mice compared to 
wild-type immunosufficient control mice (3, 32, 130). Furthermore, depletion of IFNα/β in vivo 
increases the frequency of reactivation while ex vivo treatment of latently infected cells with 
IFNγ potently suppresses the frequency of reactivation (3, 119). Of note, IFNγ, but not IFNα/β, 
controls the presence of persistent virus and the development of a large-vessel arteritis (3, 130, 
139), suggesting that type I and type II IFNs may act to control MHV68 via distinct mechanisms. 
There are several studies that have investigated the role of IFNs and their effectors on 
specific MHV68 genes. Recent studies, including our own, have demonstrated a role for both 
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type I and type II IFNs in controlling ORF 50 transcription ((47, 142) and Chapter 3). ORF 36 is 
a viral kinase that initiates the DNA damage response in infected cells by promoting 
phosphorylation of H2AX and inhibits the type I interferon response by preventing IRF-3-
mediated recruitment of RNA polymerase II to the IFNβ promoter (56, 128). ORF 54, a viral 
dUTPase, inhibits IFNα signaling by promoting degradation of its receptor (72). M2 also disrupts 
IFN signaling by downregulating STAT2 expression (75). Interestingly, IFNβ-induced IRF2 
plays a role in regulating M2 gene expression in B cells specifically; mice infected with a virus 
in which the IFN-stimulated response element (ISRE) is mutated in the M2 promoter have 
elevated titers in the lung and spleen during acute infection, increased reactivation from latency 
and greater mortality in a model of acute viral pneumonia (77). It is clear that IFNs play a critical 
role in control of MHV68 infection and that the virus has evolved mechanisms to manipulate this 
system. 
 
1.1.6 Gammaherpesvirus Latency in Pathology and Protection from Disease 
 Latent viral infection can profoundly alter the host response to a range of infectious and 
chronic inflammatory diseases. Previous studies identified a role for latent MHV68 or the 
betaherpesvirus, murine cytomegalovirus, in protecting mice from lethal bacterial challenges 
with Listeria monocytogenes or Yersinia pestis (4, 145). Similarly, latent MHV68 reduces the 
severity of some parasitic and viral infections, such as Plasmodium yoelii, influenza A virus, and 
mouse adenovirus type 1, but not West Nile virus (4, 53, 90, 108). Latent MHV68 also protects 
mice from a lethal challenge with lymphoma cells (141). When mice are lytically infected with 
MHV68 and P. yoelii, they develop severe lung inflammation (53), suggesting that the timing 
and stage of viral life cycle are critically important in the host response to coinfection. 
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Resistance to many of these challenges is associated with activation of macrophages and 
natural killer cells (4, 108, 141), suggesting that activation of the innate immune system is 
critically important in mediating many of these protective responses. Moreover, both type I and 
type II IFNs as well as tumor necrosis factor alpha (TNFα) are elevated in mice latently infected 
with MHV68 (4, 77, 113), suggesting a central role for cytokines in the orchestrating cellular 
responses in the setting of latent MHV68 infection. 
While latent MHV68 has been found to play an important role in protection from a range 
of infectious challenges, it has also been shown to exacerbate certain chronic inflammatory 
diseases, including experimental autoimmune encephalitis (EAE), a model for multiple sclerosis, 
and a model of inflammatory bowel disease (12, 89, 95). EBV has long been suggested as a 
possible trigger for multiple sclerosis (reviewed in (91)). In contrast, chronic MHV68 infection is 
associated with decreased autoantibody production and prevents kidney disease in lupus-prone 
mice (71). It is evident that latent MHV68 infection can have diverse effects in shaping the 
immune response to a range of infections and autoimmune diseases. Together these studies 
formed the basis for our investigation of the effect of latent gammaherpesvirus infection on host 
gene expression in several different organs (Chapter 4). 
 
1.2 Functions of the Products of Pervasive Transcription 
Transcription outside of known ORFs, or pervasive transcription, is increasingly 
recognized in a wide range of species (1, 5, 11, 18, 27, 51, 54, 63, 64, 115, 144, 147). Current 
estimates are that between 83.7-85.2% of the human genome is transcribed, although many 
transcripts are only produced in specific cell types, suggesting that the cellular context is 
important (10, 31, 51). 
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These regions of pervasive transcription are thought to predominately represent 
noncoding RNAs (ncRNAs). Proposed functions of ncRNAs include epigenetic modification, 
regulation of transcription (for example, by acting as co-factors to regulate transcription factors) 
as well as regulation of enzymatic pathways and modulation of post-transcriptional processing 
by regulation of mRNA splicing, transport, or translation (57, 65, 82, 131, 146). 
Some of the best studied long ncRNAs have been found to play roles in regulating gene 
transcription (reviewed in (101)). For example, XIST, which regulates X chromosome 
inactivation, and HOTAIR both repress gene transcription via interaction with Polycomb 
Repressive Complex 2 (PRC2) (102, 148). In contrast, other ncRNAs, like HOTTIP, have been 
found to promote transcription by binding to proteins, such as WDR5, to catalyze trimethylation 
of histone H3 lysine 4 (H3K4me3) (137). Interestingly, another long ncRNA, NeST, also binds 
to WDR5, promoting H3K4me3, and thereby inducing transcription of IFNγ (46). 
 
1.2.1 Functions of Noncoding RNAs in Herpesviruses 
Noncoding RNAs have been identified in several herpesviruses and it is clear that 
herpesvirus ncRNAs can play important and diverse roles in viral pathogenesis. Viral ncRNAs 
are currently divided into microRNAs (miRNAs) and “everything else” (121). Viral miRNAs 
can regulate gene expression and promote viral evasion of host defenses (121). There is a known 
cluster of viral miRNAs in MHV68 at the left end of the viral genome (6, 30, 98, 99). However, 
since the focus in this dissertation will be on long ncRNA, I will present examples of herpesvirus 
long ncRNAs which have been found to be expressed during either lytic or latent infection. 
HCMV and KSHV are both known to express ncRNAs during lytic infection while EBV, 
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Herpesvirus saimiri, and Herpes Simplex virus (HSV) are all known to produce ncRNAs during 
latent infection. 
 
1.2.2 Herpesvirus ncRNAs expressed during lytic infection 
During lytic infection, HCMV encodes a 2.7-kilobase noncoding RNA, β2.7, that can 
protect cells from apoptotic cell death (100, 121). β2.7 interacts with mitochondrial enzyme 
complex I, inhibiting its relocalization following apoptotic stimulation and promoting continued 
generation of adenosine triphosphate which is thought to be important for supporting viral 
replication in the face of signals for apoptotic cell death (100, 121). 
Extensive antisense transcription in KSHV has recently been described and several 
regions have been confirmed to encode long transcripts by northern blot, one of which is not 
associated with polysomes, suggesting that it does not encode a protein or peptides (14). The 
best-studied KSHV ncRNA is the polyadenylated nuclear (PAN) RNA which is a 1-kilobase 
nuclear ncRNA produced during lytic infection (21, 122, 149). The function of PAN RNA is 
currently unknown, but it is the focus of several recent reports. PAN RNA is activated by ORF 
50 and is the most abundant lytic transcript produced by the virus, so it is likely to play an 
important role in the viral life cycle or viral pathogenesis (15, 21, 117, 123). Recent studies to 
investigate the role of PAN RNA in viral replication have used antisense oligonucleotide (ASO) 
knockdown or a viral deletion mutant. Using ASO-mediated knockdown of PAN RNA, late, but 
not immediate-early or early, genes were decreased, suggesting a role for PAN RNA in viral 
DNA replication (7). In contrast, genes of all kinetic classes, including ORF 50, were reduced in 
a PAN RNA deletion virus (105). The discrepancy between these two studies may be due to 
incomplete knockdown of PAN RNA by ASOs or disruption of an antisense transcript in the 
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deletion virus. Recent studies have further identified an association of PAN RNA with the ORF 
50 promoter as well as the demethylases, JMJD3 and UTX, and methyltransferase, MLL2, and 
SUZ12 and EZH2, protein components of PRC2 (105, 106). It is proposed that PAN RNA can 
activate as well as repress KSHV gene expression by directing epigenetic modification of the 
ORF 50 promoter (105, 106). Interestingly, using next-generation sequencing in combination 
with chromatin isolation by RNA purification (ChIRP-Seq), investigators found that PAN RNA 
interacts with a number of viral and host genes, including host genes involved in the immune 
response (106), suggesting that this long ncRNA plays a crucial role in orchestrating viral gene 
expression and modulating the immune response to infection. 
 
1.2.3 Herpesvirus ncRNAs expressed during latent infection 
Noncoding RNAs known to be produced during latent infection include EBV-encoded 
RNAs (EBERs), Herpesvirus saimiri U RNAs (HSURs), and HSV latency associated transcript 
(LAT). EBV encodes two short nonpolyadenylated RNAs (EBER1 and EBER2) that are 
expressed at high levels during latency and reactivation of lytic replication (66, 111). These 
RNAs are known to prevent IFNα-induced apoptosis (88, 107). One proposed, but controversial, 
mechanism is that EBERs prevent apoptosis by binding to PKR and preventing its 
phosphorylation (88, 111). However, these studies used transient transfection of EBERs or in 
vitro assays to show binding of EBERs to PKR (81, 88). In infected cells, EBERs are 
predominately detected in the nucleus and are reported not to inhibit PKR phosphorylation (42, 
66, 107, 121). Other activities attributed to EBERs include induction of interleukin-10 and type 1 
IFNs via RIG-I-mediated signaling and induction of insulin-like growth factor-1 (59, 60, 68, 
109-111). 
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Herpesvirus saimiri, an oncogenic gammaherpesvirus of primates that causes  
malignant transformation of T cells, encodes seven small noncoding RNAs (HSURs 1-7) (21). 
Expression of HSURs 1 and 2 is correlated with expression of host mRNAs associated with T-
cell receptor (TCR) signaling (22). HSURs 1 and 2 induce upregulation of TCR signaling chains 
as well as signaling molecules, such as DAP10, suggesting that these viral ncRNAs contribute to 
T cell activation (22). HSURs 1 and 2 can bind to host miRNAs and HSUR1 expression is 
sufficient to downregulate one of these, miR-27 (13). Downregulation of miR-27 is associated 
with increased levels of its target protein, FOXO1, suggesting that a viral noncoding RNA can 
modulate host protein expression by regulating expression of a host miRNA (13). 
HSV, an alphaherpesvirus, encodes a latency-associated transcript (LAT) of about 9 kb 
which has been the subject of extensive study (reviewed in (104)). LAT is thought to prevent 
neurons from cell death, although its mechanism of action is unclear. Two proposed mechanisms 
are silencing of lytic gene expression and inhibition of apoptosis (104). A recent study has 
suggested that two small ncRNAs encoded by LAT inhibit apoptosis (24). The contribution of 
LAT to establishment of and reactivation from latency remains controversial (104). However, it 
has been shown that small ncRNAs, including miRNAs, can arise from LAT and regulate the 
transcriptional activator, ICP0, which supports viral replication and may promote reactivation 
(120, 132). Recent studies demonstrated that small ncRNAs encoded by LAT regulate IFNβ 
activity and have implicated LAT in gene silencing (20, 24, 138). 
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  Chapter 2: 
Pervasive transcription of a herpesvirus genome generates 
functionally important RNAs 
 
 
 
 
 
 
 
 
 
 
This chapter is from: 
Canny SP, Reese TA*, Johnson LS*, Zhang X, Duan E, Kambal A, Virgin HW. Pervasive 
transcription of a herpesvirus genome generates functionally important RNAs. mBio. 2014. 5 (2): 
e01033-13. 
 *denotes equal contribution. 
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2.1 Abstract 
 Pervasive transcription is observed in a wide range of organisms, including humans, mice 
and viruses, but the functional significance of these transcripts remains uncertain. Current 
genetic approaches are often limited by their emphasis on protein coding open reading frames 
(ORFs). We previously identified extensive pervasive transcription from the murine 
gammaherpesvirus (MHV68) genome outside of known ORFs and antisense to known genes 
(termed expressed genomic regions, EGRs). Similar antisense transcripts have been identified in 
many other herpesviruses, including Kaposi's sarcoma-associated herpesvirus and human and 
murine cytomegalovirus. Despite their prevalence, whether these RNAs have any functional 
importance in the viral life cycle is unknown, and one interpretation is that these are merely 
"noise" generated by functionally unimportant transcriptional events. To determine whether 
pervasive transcription of a herpesvirus genome generates RNA molecules that are functionally 
important, we used a strand-specific functional approach to target transcripts from thirteen EGRs 
in MHV68. We found that targeting transcripts from six EGRs reduced viral protein expression, 
proving that pervasive transcription can generate functionally important RNAs. We characterized 
transcripts emanating from EGRs 26 and 27 in detail using several methods, including RNA 
sequencing, to finely map several novel polyadenylated transcripts that were enriched in the 
nucleus of infected cells. These data provide the first evidence of the functional importance of 
regions of pervasive transcription emanating from MHV68 EGRs and demonstrate that 
transcripts from genome regions outside of known ORFs in herpesviruses can play critical roles 
in the viral life cycle.  
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2.2 Introduction 
Gammaherpesviruses are oncogenic herpesviruses that undergo productive replication 
and can establish latent infection in their hosts. Human gammaherpesviruses, Epstein-Barr Virus 
(EBV, HHV-4) and Kaposi's sarcoma-associated herpesvirus (KSHV, HHV-8), are associated 
with malignancies, including Burkitt's and primary effusion lymphomas, nasopharyngeal 
carcinoma, and Kaposi's sarcoma. Murine gammaherpesvirus 68 (MHV68, γHV68, MuHV4) is 
genetically related to EBV and KSHV and causes lymphomas and lymphoproliferative disease in 
immunocompromised mice (13, 34, 51, 52, 58), providing a tractable model system in which to 
study productive infection in vitro and viral pathogenesis in vivo. 
MHV68 and other herpesviruses can serve not only as models for viral infection and 
pathogenesis, but also as systems in which to unravel the complexity of pervasive transcription 
and to probe the function of its products. Using high density tiled arrays and RNA sequencing, 
we and others have shown that widespread transcription occurs outside of annotated open 
reading frames (ORFs) during lytic MHV68 infection, generating regions of transcription termed 
expressed genomic regions (EGRs) (8, 25). We termed these EGRs rather than genes because the 
signal in a tiled array analysis may represent multiple different transcripts, and because they 
were not initially investigated for functional importance. These EGRs contain no ORFs with 
significant homology to known proteins and, as such, may encode noncoding RNAs (ncRNAs), 
spliced transcripts, and/or novel small polypeptides (25). While there are several well-studied 
examples of herpesvirus ncRNAs expressed during lytic or latent infection (reviewed in (50)), 
new sequencing and array technologies reveal a substantially more complex transcriptional 
landscape for both betaherpesviruses and gammaherpesviruses than was previously appreciated 
(7, 8, 10, 14, 25, 26, 36, 62, 64). Intergenic and antisense transcription has also been widely 
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described in a range of other organisms including humans and mice (2, 11, 20, 28). However, the 
function of these viral transcripts remains an open question. The implications of these findings 
for genomic mutagenesis studies targeting ORFs within herpesvirus genomes are incompletely 
understood. Importantly, while initial findings of pervasive transcription of the MHV68 genome 
(25) have been independently confirmed (8), whether these RNAs have any function is unknown. 
One reasonable interpretation is that the products of pervasive transcription are irrelevant to the 
viral life cycle and might merely be the result of failed termination of functionally important, 
often protein-coding, transcripts. Studies relying on disruption of the viral genome in ways that 
alter transcripts from both genomic strands cannot resolve this question. 
In this study, we used a flow cytometry-based screen combined with strand-specific 
knockdown of candidate RNAs to assess the importance of RNAs encoded within EGRs. We 
found that targeting several EGR-encoded transcripts altered the expression of other viral genes 
and selected two adjacent regions (EGRs 26 and 27) for detailed analysis. We characterized the 
transcript architecture, localization, and effects on other viral genes for RNAs emanating from 
EGRs 26 and 27. Herein, we report that EGR 26 and 27 transcripts were enriched in the nucleus 
of infected cells and that targeting EGR 27 transcripts altered expression of multiple viral genes. 
To our knowledge, this is the first proof of functional significance of novel viral transcripts 
identified using a transcriptome-based approach. 
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2.3 Results 
2.3.1 Establishment of a system to target MHV68 transcripts: antisense targeting of a 
known essential gene alters late viral protein expression. 
 Since many EGRs are antisense to other EGRs or known ORFs, it was necessary to 
design a strategy to determine the functionality of transcripts from a single strand of the viral 
genome. To disrupt viral transcripts in a strand-specific manner, we designed single-stranded 
antisense oligonucleotide (ASO) gapmer probes to known MHV68 viral genes. Gapmer ASOs, 
which are reported to disrupt gene expression by RNase-H mediated degradation of their target 
transcript (60), have been previously used to target herpesvirus ncRNAs (3, 6). 
An ASO to the single-stranded DNA binding protein, ORF 6 (53), significantly reduced 
transcript (Fig. 2.1A) and protein levels (Fig. 2.1B) of its target. An ASO to a non-cellular, non-
viral transcript (GFP) did not alter ORF 6 transcript or protein abundance (Fig. 2.1A-B) and 
served as a negative control. Additionally, the ORF 6 ASO reduced the abundance of the ORF 4-
ORF 6 biscistronic transcript (Fig. 2.1A, (27)). We observed a smaller (~1kb) band in cells 
transfected with the ASO to ORF 6, which may represent a stable product of the degraded ORF 6 
transcript (Fig. 2.1A). These data demonstrated that targeting a viral gene with an ASO 
decreased both transcript and protein levels of its target, confirming this as an effective strategy 
for knocking down specific transcripts in MHV68 infected cells. 
We next validated a flow cytometry-based assay to rapidly assess the effect of 
knockdown of transcripts on viral protein expression. We selected the late viral gene ORF 4, the 
viral complement regulatory protein (v-RCA), expressed on the surface of infected cells (27), to 
measure the effect of viral transcript knockdown on a late stage of the viral life cycle. An ASO to 
the essential gene, ORF 6 (53), significantly inhibited the surface expression of ORF 4 (Fig. 
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2.1C). An ASO designed to be complementary to the nonessential gene, M3 (56), did not reduce 
ORF 4 surface expression (Fig. 2.1C). Since ORF 4 is transcribed as a bicistronic transcript with 
ORF 6, it is possible that the reduction in ORF 4 surface expression observed was due to direct 
knockdown of the transcript that encodes ORF 4 by the ASO designed to target ORF 6. To 
confirm that knocking down ORF 6 altered expression of other late proteins, we evaluated 
protein expression of ORF 26 and M9 (ORF 65) (4, 12) and confirmed that knocking down ORF 
6 decreased expression of multiple late proteins (Fig. 2.1D). These data demonstrated that 
disrupting the expression of an essential gene transcript was detectable by a change in ORF 4 
surface expression and indicated that this method could be used as a screening tool for the 
function of EGR transcripts. 
 
2.3.2 Targeting EGR transcripts alters surface expression of the late viral protein 
encoded by ORF 4. 
 To determine whether transcripts encoded within EGRs played a role in productive 
infection, we designed ASOs to regions within 13 EGRs (EGR nomenclature as in (25)). We 
selected 12 EGRs that might be important for viral replication (EGRs 9, 10, 11, 15, 16, 18, 20, 
21, 23, 25, 26, and 27) and one EGR that might be dispensable for viral replication (EGR 30) 
based on results from a genome-wide transposon-based mutagenesis screen of the MHV68 
genome (48). Since transposon mutagenesis disrupts genetic elements on both DNA strands, 
some of the phenotypes previously attributed to transposon insertions in known ORFs could also 
be explained by a function of EGR-encoded transcripts from the opposite strand. Cells were 
transfected with ASOs to regions of the 13 selected EGRs or known viral genes, ORF 6 or M3, 
infected with MHV68, and then analyzed for ORF 4 surface expression by flow cytometry (see 
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Table 2.1 for ASO sequences and targeted genomic coordinates). ASO targeting of EGRs 9, 16, 
18, 23, 26 and 27 showed statistically significant reductions in ORF 4 surface expression (Fig. 
2.2). For EGRs 9, 18, and 23, which were targeted with multiple ASOs, not all ASOs altered 
ORF 4 expression, suggesting that these ASOs may differ in knockdown efficiency or may target 
distinct transcripts encoded by the EGR. In fact, we have found that there is extensive splicing 
within the MHV68 transcriptome, including within EGR 23, which may account for the 
differences observed (Johnson, L.S., Canny, S.P., Virgin, H.W., unpublished data). Cells 
transfected with ASOs targeting EGRs 11 and 20 had increased ORF 4 surface expression (Fig. 
2.2), which might suggest a role for transcripts emanating from these EGRs in suppressing viral 
replication. 
Taken together, these results show that several EGR-encoded transcripts were important 
for ORF 4 protein expression. ASOs to the adjacent EGRs 26 and 27 (EGR 26c and EGR 27b in 
Table 2.1) on the negative strand of the viral genome had the largest effect on cell surface 
expression of ORF 4, comparable to the effect of targeting the essential gene, ORF 6 (Fig. 2.2). 
For this reason, we chose to further characterize EGR 26-27 encoded transcript(s) and to assess 
the effect of targeting RNAs from this region on viral gene expression. 
 
2.3.3 Mapping 5' and 3' ends of EGR 26 and EGR 27 transcripts. 
 To define the transcript(s) targeted by ASOs to EGRs 26 and 27, we used a combination 
of RNA sequencing, 5' and 3' RACE, and northern blot analysis. First, we confirmed active RNA 
expression within EGRs 26 and 27 in lytically infected fibroblasts by RNA sequencing and 
identified a transcriptional signal similar to the signal that we had previously detected using tiled 
array technology (Fig. 2.8 and (25)). Spearman correlations calculated between our previous 
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tiled array data and RNA sequencing datasets from 18 hours post infection (hpi) yielded 
correlation coefficients ranging from 0.78 to 0.85. 
To determine the size and relative position of transcripts emanating from EGRs 26 and 
27, we used northern blot analysis. We identified a ~12 kb transcript (hereafter EGR 26 
transcript A) that overlapped EGRs 26 and 27 and ORFs 65-67; an ~8 kb transcript (hereafter 
EGR 27 transcript A) that overlapped EGR 27 and ORFs 65-67; and a ~3 kb transcript (hereafter 
EGR 27 transcript B) that overlapped EGR 27 (Fig. 2.3). We also identified a transcript > 12 kb 
that was detected by probe 1 which we termed EGR 26 transcript B, but did not map further. 
Using a probe to genomic coordinates 101170-101208 (probe 12, Fig. 2.3A), we detected a ~ 8 
kb transcript and a ~3 kb transcript on the opposite side of the 100-bp internal repeat (Fig. 2.3B), 
suggesting that both EGR 27 transcripts A and B overlap the 100-bp internal repeat. We tested 
two gene-specific primers in the PCR step of 5' RACE for EGR 27 and obtained comparable 
results. We identified 9/9 colonies within one nucleotide of 101225. We were unable to detect 
transcripts using probe 13, suggesting that ~101225 was the 5' end for both EGR 27 transcripts A 
and B (Fig. 2.3B). Probe 8, but not probes 9 or 10, detected a ~ 12 kb transcript, comparable in 
size to EGR 26 transcript A (Fig. 2.3A-B). 5' RACE analysis identified 6/6 colonies within four 
nucleotides of 97790 (1 colony at 97786, 1 colony at 97789, 3 colonies at 97790, and 1 colony at 
97791), suggesting that the 5' end of EGR26 transcript A was ~97790.   
EGRs 26 and 27 encode polyadenylated transcripts as shown by northern blot analysis of 
polyadenylated RNA (data not shown and Fig. 2.3) and confirmed by RNA sequencing of 
polyadenylated RNA (Fig. 2.8). To identify 3' ends of EGR 26 and 27 transcripts, we mined 
RNA sequencing data from four experiments, two from 18 hpi and two from 6 hpi, using a 
custom analysis pipeline. By mining RNA sequencing data for polyadenylated reads, we 
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identified 3' ends within the EGRs 26 and 27 at 85207, 93842, and 98510 and within the 
intervening ORFs at 95322, 95758, and 95895 (Fig. 2.8 and Table 2.3). It is worth noting that 
these 3' ends at 95322, 95758, and 95895 were not attributable to transcripts detected by northern 
blot, suggesting that there may be additional less abundant transcripts within this region. This is 
important because it indicates that northern blot analysis may not be sensitive enough to detect 
all transcripts encoded within EGRs that might be targeted by specific ASOs. We performed 3' 
RACE analysis to confirm 3' ends at 98510 (6/6 colonies) and within 3 nucleotides of 93842 (5/5 
colonies). In addition, our RNA sequencing approach confirmed six previously known 
polyadenylation sites as well as 53 novel sites downstream of known protein-coding and EGR-
encoded transcripts; the majority of these were detected at both 6 and 18 hpi (Table 2.3). 
Together, these data identified three transcripts that overlap the EGR 26-27 region and highlight 
the profound transcriptional complexity across the MHV68 genome (Fig. 2.3 and (8, 25, 32)). 
 
2.3.4 EGR 26 and EGR 27 transcripts are enriched in the nucleus of infected cells. 
 To determine if transcripts that overlap EGRs 26 and 27 were retained in the nucleus or 
exported to the cytoplasm of infected cells, we separated nuclear and cytoplasmic fractions, 
extracted RNA, and probed for EGR 26 transcript A using probe 2 and EGR 27 transcripts A and 
B using probe 11. We confirmed adequate separation of nuclei from cytoplasm by western and 
northern blot analyses of known cytoplasmic and nuclear proteins and RNAs with only modest 
contamination of the cytoplasmic fraction with nuclear protein and RNA (Fig. 2.4). We found 
that the EGR 26 transcript A, EGR 27 transcript A, and EGR 27 transcript B were enriched in the 
nuclear fraction (Fig. 2.4B). Nuclear enrichment of EGR 26 and EGR 27 transcripts was 
comparable to the well-characterized mouse nuclear ncRNA, nuclear enriched abundant 
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transcript 2 (Neat2, also known as Malat1, (23), Fig. 2.4B). Analysis of representative viral 
(ORF 6) and host (actin) protein-coding transcripts demonstrated that these translated transcripts 
accumulated in the cytoplasm (Fig. 2.4B). The nuclear distribution of EGR 26 transcript A, EGR 
27 transcript A, and EGR 27 transcript B was consistent with a known nuclear ncRNA and not 
with protein-coding transcripts, suggesting that these EGR transcripts may be nuclear ncRNA. 
 
2.3.5 Targeting EGR 27 transcripts alters surface expression of ORF 4 protein. 
 To determine the effect of knockdown of RNAs encoded within EGR 27 on ORF 4 
surface expression, we targeted this region with four ASOs, two of which we predicted would 
target both EGR 27 transcripts detectable by northern blot and two of which we predicted would 
specifically target EGR 27 transcript A. Because EGR 27 transcript A overlaps the entire length 
of EGR 27 transcript B, it was not possible to specifically target the smaller transcript. EGR 27a 
and EGR 27b ASOs reduced the abundance of both EGR 27 transcripts as predicted (Fig. 2.5B-
C). Surprisingly EGR 27d ASO also significantly reduced EGR 27 transcript B although it was 
not predicted to target this transcript (Fig. 2.5C), raising the possibility that an additional 
transcript might be derived from this region. In support of this hypothesis, we identified 
additional 3' ends ORFs 66-67 at 95322, 95758, and 95895 that have not been ascribed to 
specific transcripts (Table 2.3) that were not attributed to RNAs detected by northern blot (see 
above), suggesting the presence of additional as-yet-unmapped transcripts within this region. As 
predicted, EGR 27c ASO reduced EGR 27 transcript A, but not EGR 27 transcript B (Fig. 2.5B-
C). All EGR 27 ASOs reduced ORF 4 surface expression (Fig. 2.5E). While we cannot attribute 
the effect on ORF 4 surface expression to a specific transcript because the transcripts overlap, 
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these data confirm data in our initial screen (Fig. 2.2) by showing that RNAs encoded in this 
region of the genome are functionally important for viral gene expression. 
We also targeted EGR 26 with six ASOs, five predicted to target EGR 26 transcript A 
(EGR 26a-e) and one directed 3' of EGR 26 transcript A (EGR 26f). EGR 26b-d ASOs 
significantly reduced EGR 26 transcript A levels (Fig. 2.5D). Although EGR 26d ASO reduced 
EGR 26 transcript A, it did not significantly reduce ORF 4 surface expression (Fig. 2.5E), 
suggesting that the effect on ORF 4 surface expression by other EGR 26 ASOs may be due to 
other smaller transcripts in this region (see Fig. 2.3B). The effect of EGR 26f ASO, which did 
not target EGR 26 transcript A, but likely targeted other RNAs derived from EGR 26, such as 
EGR 26 transcript B, further supports that RNAs derived from EGR 26 are important for viral 
protein expression. These data suggest that similar to those transcripts emanating from EGR 27, 
RNAs from EGR 26 are also functionally relevant and that the functional significance of EGR 
transcription is not restricted to a single region of the genome. 
To determine whether the observed changes in ORF 4 protein expression were associated 
with a detectable change in viral replication, we analyzed viral titers at 24 hpi in ASO-
transfected cells. We detected a modest reduction in viral titer in cells transfected with EGR 27a, 
EGR 27b, EGR 27d, and EGR 26c ASOs, comparable to the reduction in viral titer in cells 
transfected with an ASO to the essential gene, ORF 6 (Fig. 2.5F). Although the effects were 
modest, likely due to partial knockdown of the target message, it is notable that the EGR ASOs 
significantly reduced viral titers. 
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2.3.6 Targeting of EGR 27 transcripts alters expression of multiple viral genes. 
 Having shown that RNAs derived from EGRs can be functionally important as measured 
by the effects on a viral late protein and viral replication, we next assessed the extent of ASO 
effects on different aspects of viral transcription and protein expression. To confirm that EGR 27 
ASOs reduced late gene expression, we assessed the effect of EGR 27 ASOs on ORF 26 and M9 
(ORF 65) protein expression by western blot analysis and spliced ORF 29 transcripts by qRT-
PCR (35). EGR 27a-d ASOs reduced ORF 26 and M9 protein expression and ORF 29 transcript 
expression (Fig. 2.6A-B). These data show that targeting EGR 27 transcripts broadly altered the 
expression of multiple late genes and did not exert effects restricted to surface expression of the 
late protein encoded by ORF 4. 
Next, we tested the effect of EGR 27 ASOs on the expression of the early gene, ORF 6 
(59), or the immediate-early gene, ORF 50, also known as the replication and transcription 
activator (RTA) (37). We found that EGR 27a, 27b and 27d ASOs, but not EGR 27c ASO, 
significantly reduced ORF 6 transcript levels (Fig. 2.6C). However, all EGR 27 ASOs reduced 
ORF 6 protein levels (Fig. 2.6D). Furthermore, we found that EGR 27a and 27d ASOs, but not 
EGR 27b or 27c ASOs, significantly reduced the abundance of spliced ORF 50 transcripts (Fig. 
2.6E). In summary, these data suggest that a transcript or transcripts targeted by EGR 27a and/or 
27d ASOs acts early in the viral lifecycle, altering gene expression of specific viral genes from 
each kinetic class. Furthermore, a transcript(s) targeted by EGR 27c ASO may act later in the 
viral lifecycle. 
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2.3.7 EGR 26c ASO decreases specific genes of all kinetic classes. 
 We evaluated EGR 26c ASO, the ASO used in our initial screen (Fig. 2.2), for its effect 
on the viral lifecycle. To confirm that EGR 26c ASO altered the expression of multiple late 
genes, we analyzed its effect on the expression of early-late (M3) and late (M9) genes (46, 57, 
59) using northern and western blot analyses. We found that EGR 26c ASO reduced M9 and M3 
protein levels (Fig. 2.7A and 2.7C) as well as M9 and M3 transcript levels (Fig. 2.7B and data 
not shown). Taken together with the effect of EGR 26c ASO on ORF 4 cell surface expression, 
these data demonstrate that a transcript targeted by EGR 26c ASO was important for expression 
of several early-late and late genes and suggested that it acted upstream of their expression. 
Interestingly, EGR 26c ASO did not alter the level of EGR 27 transcript A, detected by the 
northern blot probe 7 (data not shown), indicating that EGR 26c ASO altered the levels of 
specific viral RNAs rather than overall transcription of the viral genome. 
Next, we tested the effect of EGR 26 ASOs on the expression of ORF 6 and found that 
EGR 26a-c ASOs reduced ORF 6 transcript levels, while EGR 26d-f ASOs did not (Fig. 2.7D), 
suggesting that a transcript targeted by EGR 26a-c ASOs acts to reduce viral gene expression. 
EGR 26c ASO also reduced ORF 6 protein levels (Fig. 2.7E). Finally, we tested whether EGR 
26c ASO altered the expression of ORF 50 by qRT-PCR. We found that EGR 26c ASO 
significantly reduced the abundance of spliced ORF 50 transcripts (Fig. 2.7F). Northern blot 
analysis using probe 2 on RNA selected for polyadenylated transcripts revealed the presence of 
smaller transcripts that might be targeted by EGR 26c ASO (see Fig. 2.3B). The fact that EGR 
26a-c ASOs all reduce ORF 6 transcript abundance (Fig. 2.7D) suggests that a transcript that 
overlaps genomic coordinates 85576 to 85891 acts early in the viral life cycle, affecting gene 
expression of multiple specific viral genes. 
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2.4 Discussion 
 In this paper, we provide the first data demonstrating that pervasive transcription of a 
herpesvirus genome, identified by pan-genomic analysis of RNA expression using both tiled 
arrays and RNA sequencing can generate functionally important RNAs for viral gene and protein 
expression. This is significant because it was unknown whether extensive antisense transcription 
observed by many groups from various herpesvirus genomes is functionally important or is due 
to "read-through" transcription that results in large amounts of functionally irrelevant RNA. We 
identified six EGRs that generate transcripts that altered ORF 4 surface expression. Upon 
examining transcripts encoded by two EGRs in more detail, we confirmed that targeting 
transcripts from the strand of the genome antisense to known protein coding genes alters multiple 
parts of the viral transcriptional and translational program.  
These data have fundamental implications for the approach to and interpretation of 
genetic studies and highlight the importance of mapping transcripts derived from the strand 
opposite to ORFs. A limitation of traditional genetic approaches is the emphasis on ORFs and 
the utilization of genetic approaches that alter the sequence of both strands of the viral genome. 
This approach has been very fruitful, but misses an important layer of complexity to viral gene 
regulation revealed here. One of our most notable findings is the extreme complexity of 
transcripts emanating from EGRs and the fact that many of these transcripts are polyadenylated 
but remain concentrated in the nucleus. Furthermore, our data suggest that in some cases there 
may be important contributions of less abundant transcripts whose presence may be difficult to 
detect using classical methods (see EGR 26 as an example). Taken together, our results support 
the use of sensitive technologies, such as next-generation RNA sequencing, in transcript analysis 
and the necessity of considering antisense transcripts in genetic analyses of herpesviruses and 
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designing functional experiments to evaluate the function of each strand of the viral genome 
independently. 
 
2.4.1 Implications of transcriptional complexity of EGR-encoded RNAs  
 It is interesting to reconsider previous findings in view of the transcriptional complexity 
underlying the MHV68 genome. Here, we have reported a region of the MHV68 genome in 
which detailed analysis reveals at least five transcripts overlapping the late capsid protein, M9 
(ORF 65), each of which may play distinct roles for the virus (5, 41). Previous studies using 
RNase protection assays and qRT-PCR have identified the M9 region as: (i) a candidate region 
of latent gene expression; (ii) a component of the virion; and (iii) producing an RNA with 
immediate-early kinetics (22, 46, 59). We note that previous analyses are complicated by the 
presence of multiple overlapping transcripts because probes designed to M9 detect five 
independent transcripts (including EGR 26 transcript A and EGR 27 transcript A). 
Additionally, our results suggest that caution should be used for interpretation of 
transposon screens (39, 48). Because ~90% of EGR nucleotides overlap with transcription on the 
opposite strand ((25) and Fig. 2.8), any mutagenesis strategy that disrupts both strands may alter 
functionally relevant transcripts derived from either strand. For example, transcripts encoded by 
EGRs 26 and 27 are antisense to known protein-coding ORFs 63, 64, 68 and 69. ORFs 63 and 64 
are predicted to be essential tegument proteins, ORF 68 an essential glycoprotein, and ORF 69 
an essential gene of unknown function (48, 58). Thus, while these transposon screens provide 
invaluable functional data, defining the genetic elements responsible for observed phenotypes 
will need to incorporate the transcriptional complexity of each region and subsequently utilize 
strand-specific approaches for functional analysis. 
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2.4.2 Potential mechanism for EGRs 26 and 27 transcript function. 
 Our studies show that transcripts encoded by EGRs are functionally important and effect 
multiple parts of the viral life cycle, but do not identify specific viral transcripts with individual 
functions relevant to viral transcription and protein expression. The reduction in ORF 50 
transcript expression that we observed following targeting with EGR 27a and 27d ASOs and the 
nuclear localization of EGR 27 transcripts is consistent with transcripts targeted by these ASOs 
functioning to epigenetically regulate the ORF 50 promoter(s). There is a growing consensus in 
the mammalian ncRNA literature that epigenetic modification of chromatin is a key function of 
long ncRNAs (1, 29, 44, 45, 54). Interestingly, the KSHV ncRNA, polyadenylated nuclear 
(PAN) RNA, associates with the ORF 50 promoter as well as the demethylases, JMJD3 and 
UTX, and the methyltransferase, MLL2 (47). Many studies highlight the importance of 
epigenetic modifications in controlling herpesvirus gene expression, and herpesvirus proteins can 
interact with histone deacetylases (HDACs) to prevent gene silencing (9, 19, 30, 42, 49). We and 
others have identified several important modifications that silence ORF 50 in macrophages, B 
cells, and cells from latently infected mice, including methylation of the distal ORF 50 promoter 
(16, 17) and recruitment of HDACs and the nuclear receptor corepressor (NCoR) to the core 
ORF 50 promoter (15, 63). It is intriguing to speculate whether transcripts targeted by EGR 27a, 
27d, and/or 26c ASO may act as a molecular scaffold for chromatin modifying proteins or 
prevent the association of known repressive complexes with ORF 50 promoters in lytically 
infected fibroblasts. 
 In contrast, EGR 27c ASO, which specifically targeted EGR 27 transcript A, did not 
reduce ORF 50 transcript expression, suggesting that this RNA may act later in the viral life 
cycle, playing a role in viral DNA replication or virion assembly. Interestingly, a role for an 
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EBV RNA, BHLF1 transcript, has been recently described in DNA replication; BHLF1 
transcript forms an RNA-DNA hybrid molecule at the origin of lytic replication (OriLyt) and is 
important for recruitment of the viral single stranded binding protein, BALF2, to OriLyt (43). 
These results suggest that RNAs derived from EGRs may play a range of different roles in viral 
replication and merit further investigation and consideration in functional studies. 
  
Many new transcripts have been identified not only in MHV68 but also in important 
human pathogens, including KSHV and HCMV (7, 14, 36, 62, 64). Our results suggest that 
transcripts in each of these viruses may play crucial roles in the viral life cycle and/or in viral 
pathogenesis, and that strand-specific approaches combined with detailed transcriptional analysis 
similar to ours will allow for identification of novel transcripts critical for viral gene expression 
and infection. 
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2.5 Materials and Methods 
2.5.1 Cells, virus, and virus assays. 
 NIH 3T12 fibroblasts (ATCC CCL-164) were grown in Dulbecco’s modified Eagle 
medium (DMEM) containing 5% fetal calf serum (FCS), 2 mM L-glutamine, and 10 mM 
HEPES. Cells were infected with MHV68 clone WUMS (ATCC VR-1465) for 1 hour at 37ºC at 
a multiplicity of infection (MOI) of 5 or 10 as indicated. Viral passage and titer were performed 
on NIH 3T12 fibroblasts as described (61) except that cells were overlaid with 2% 
methylcellulose in MEM supplemented with 5% FCS and 2 mM L-glutamine. 
 
2.5.2 Antisense oligonucleotides. 
 Custom antisense gapmer oligonucleotides (ASOs) containing a phosphorothioate 
backbone and locked nucleic acid (LNA) residues to increase probe stability and knockdown 
efficiency (18, 24, 31) were designed and synthesized by Exiqon (Woburn, MA) to target viral 
transcripts (Table 2.1). Gapmers contain LNA bases at their ends surrounding a central stretch of 
DNA enabling RNase H-mediated cleavage of their targets (60). Transfections were performed 
with 40 pmol of ASO per 105 cells using Lipofectamine 2000 (Life Technologies, Grand Island, 
NY) according to the manufacturer's instructions. An ASO designed to target GFP was used as a 
negative control. Cells were infected with MHV68 six hours after transfection and harvested at 
the indicated times post infection. Toxicity was assessed by alamarBlue (Life Technologies) at 
30 hours post transfection according to the manufacturer's instructions. There was no association 
of toxicity relative to untransfected cells as assessed by alamarBlue and phenotype as assessed 
by ORF 4 surface staining (Spearman's Correlation, p=0.8250). 
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2.5.3 Western blot analysis, antisera and antibodies. 
 For MHV68 western blot analysis, samples were lysed at 18 hpi in 2x Laemmeli buffer, 
subjected to protein electrophoresis on 4-15% or 4-20% Tris gradient gels (Bio-Rad), and then 
transferred to polyvinylidene difluoride membrane. For western blot analysis of subcellular 
fractions, 2x Laemmeli buffer was added to samples lysed in the relevant buffer as described 
below (Subcellular Fractionation). 4 μg of protein per sample was subjected to protein 
electrophoresis on a 10% Tris gel, then transferred to polyvinylidene difluoride membrane.  
Antibodies used were anti-Lamin B1 (AbCam), anti-GAPDH (clone GAPDH-71.1) (Sigma, St. 
Louis, MO), anti-calreticulin (clone 16/Calreticulin) (BD Biosciences), polyclonal rabbit antisera 
generated to ORF 6 (40), M3 (55), ORF 26 (4) or M9 (4) and a goat anti-rabbit or goat anti-
mouse HRP-conjugated secondary antibody as appropriate (Jackson Immunoresearch, West 
Grove, PA). MHV68 western blots were stripped and reprobed with anti-beta-actin (clone AC-
74) (Sigma) and then with a goat anti-mouse HRP-conjugated secondary antibody (Jackson 
Immunoresearch) to control for loading. Blots were developed with ECL Plus chemiluminescent 
reagent (GE Healthcare Life Sciences) or Pierce ECL chemiluminescent reagent (Thermo 
Scientific) and imaged using film or a Storm 840 phosphorimager. Bands were quantitated using 
ImageJ (NIH). For each sample, the indicated protein was normalized to the actin loading 
control. 
 
2.5.4 Flow cytometric analysis for detection of surface expression of ORF 4 protein. 
 At 24 hpi, cells were removed from tissue culture dishes by gentle scraping after 
incubation in a 0.02% EDTA solution for 10 minutes at 4ºC. Cells were fixed in 2% 
formaldehyde and stained using anti-ORF 4 antiserum (27) at 1:10,000 or preimmune rabbit 
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serum (Cocalico Biologicals, Reamstown, PA), followed by donkey anti-rabbit DyLight 649 
secondary antibody (Biolegend, San Diego, CA). Flow cytometry was performed with a 
FACSCalibur (BD Biosciences, San Jose, CA). Data were analyzed by FlowJo (Tree Star; 
Ashland, OR). 
 
2.5.5 RNA sequencing (RNA-Seq) library construction and expression analysis. 
 Total RNA was isolated from TRIzol (Life Technologies) as described (25) at 6 or 18 hpi 
as indicated. Poly(A) selected RNA was chemically fragmented using RNA Fragmentation 
Reagents (Life Technologies) and purified using RNeasy MinElute Cleanup columns (Qiagen). 
Directional RNA-Seq libraries were generated using 600 nanograms of fragmented 18 hpi RNA 
according to Illumina’s directional mRNA-Seq protocol or 200 nanograms of 6 hpi RNA 
according to Illumina's directional Tru-Seq protocol. Nucleotides with a Phred quality score less 
than 20 were trimmed from the 3' end of raw Illumina reads. Trimmed reads with a mean quality 
score less than 10 or a length less than 20 were discarded. Reads were then mapped to mouse 
rRNA, MHV68 genome (GenBank accession number: U97553), and mouse genome sequences 
(Build 37) with the short read aligning program Bowtie-0.12.5 (33). Bowtie alignments were 
performed using the parameter settings “--best” and " -e 420" or "-e 600" settings for 76 
nucleotide or 100 nucleotide reads, respectively. Bowtie output from the MHV68 genome 
mapping was converted to wig files of read depth coverage, on a log2 scale, and visualized using 
Gbrowse (www.gbrowse.org). Correlation coefficients between read depth coverage and tiled 
array signals were calculated using Spearman’s ranked correlation coefficient in the R statistical 
environment. Sequencing data are available at the National Center for Biotechnology 
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Information (NCBI) Sequence Read Archive (SRA) accession numbers SRX403400 to 
SRX403403 for samples at 6 hpi and SRX403404 to SRX403407 for samples at 18 hpi. 
 
2.5.6 Identification of polyadenylated reads from RNA-Seq data sets. 
 3'-terminal adenosine (A) residues were trimmed from filtered reads with greater or equal 
to five 3’ terminal A's. Both trimmed and untrimmed reads were mapped to MHV68 with Bowtie 
with default “-e” settings. Mapped reads that contained at least five non-genomic A's were 
considered putative polyadenylated reads. If a potential polyadenylation cleavage site was 
located within or downstream of a stretch of genomic A's, the coordinates of this potential site 
was moved upstream of the genomic poly(A) stretch to maintain consistency. Sites that were 
located adjacent to a stretch of seven or more genomic A's were excluded due to the possibility 
that during RACE validation such sites could provide false internal priming of the oligo-dT 
primer. Those sites with an average of at least five supporting reads between biologic replicates 
were clustered. The site reported in Table 2.3 is that with the most supporting reads in 30 
nucleotide sliding windows. Raw read quality filtering and the identification of putative 
polyadenylated reads were done using a combination of Linux utilities and custom Perl scripts, 
available upon request. 
 
2.5.7 Rapid Amplification of cDNA Ends (RACE). 
 5' and 3' transcript ends were identified by RACE using Invitrogen's 5' and 3' RACE 
systems according to the manufacturer's instructions. cDNA was generated from total RNA 
extracted 18 hpi using a gene-specific primer (for 5' RACE) or an oligo(dT)-containing adapter 
primer (for 3' RACE). PCR amplification was performed using gene-specific primers with 
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Invitrogen's amplification primers. The following gene-specific primers were used for reverse 
transcription in 5' RACE: EGR 26 transcript A: 5'-CGATCAGGTGGCTCAACTGG-3'; EGR 
27: 5'-GCGAGGAGCAGCACAGCAGA-3'. For 5' RACE reactions, the PCR primers used were 
as follows: EGR 26 transcript A: 5'-CTGCTCACATACAAGGTATCTGG-3'; EGR 27: 5'-
GCAGAGGTCCGTCCAGTAGCGA-3' and 5'- GGTCCGTCCAGTAGCGA-3'. For 3' RACE 
reactions, the PCR primers used were as follows: EGR 27 transcript A: 5'-
GCCAGACATTCGCACAACAC-3'; EGR 27 transcript B (B1): 5'-
CGAGATACAATGTTGAAGCATTCA-3'. The resulting PCR products were gel purified and 
ligated into a pCR4-TOPO TA sequencing vector (Life Technologies). Universal M13 forward 
and reverse primers were used for sequencing. 
 
2.5.8 Northern blot analysis. 
 Total RNA was isolated as described (25) at 14 or 18 hours post infection (hpi) as 
indicated. Templates for northern probes were amplified by PCR from viral or mouse genomic 
DNA (using PCR primers listed in Table 2.2), prepared as described in (25) for probes 2 and 7 
(formerly EGR 26 probes 1 and 4 (25), respectively), or obtained from a commercial vendor for 
actin (Life Technologies). Northern blotting using Ambion's NorthernMax kit (Life 
Technologies, Grand Island, NY) and generation of single-stranded P32-labeled RNA probes 
using the Maxiscript Sp6/T7 kit (Life Technologies) were performed as described (25). Probe 12 
was generated using the mirVANA miRNA Probe Construction kit (Life Technologies) 
according to the manufacturer's instructions. Five micrograms of total RNA were used for all 
northern blot analysis unless otherwise stated. Membranes were scanned using a Storm 840 
Phosphorimager and quantitated using ImageQuant TL (GE Healthcare Biosciences, Pittsburgh, 
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PA). For quantitation of each sample, the indicated transcript signal was normalized to the signal 
from the actin loading control. 
 
2.5.9 Subcellular Fractionation. 
 Nuclei were separated from cytoplasm using a protocol adapted from published methods 
(21). Briefly, 3T12 cells were removed from plates by trypsinization at 18 hpi and centrifuged to 
pellet cells. After washing with PBS, the pellet was resuspended in 150 mM NaCl, 50 mM 
HEPES, 1% NP40 and 1 U/μl SUPERase-In RNase Inhibitor (Ambion) to disrupt non-nuclear 
membranes and incubated on ice for 30 minutes. The lysate was centrifuged at 7000 RCF to 
pellet the nuclei, and the supernatant removed for RNA and protein analysis (cytoplasmic 
fraction). After washing with PBS, the nuclear pellet was resuspended in cold 150 mM NaCl, 50 
mM HEPES, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, and 1 U/μl SUPERase-
In RNase Inhibitor (Life Technologies) to disrupt the nuclear membrane and incubated for two 
hours at 4ºC with rotation. RNA was extracted from lysates using TRIzol LS (Life Technologies) 
and analyzed by northern blot as described above. Approximate cellular equivalents were 
calculated based on the relative amounts of RNA recovered from nuclear and cytoplasmic 
fractions. For comparison, unfractionated cells were collected in TRIzol (Life Technologies) and 
then processed to isolate RNA according to the manufacturer's instructions. Samples were also 
analyzed by western blot to ensure adequate separation of fractions as described above. 
 
2.5.10 Quantitative reverse transcriptase-PCR (qRT-PCR). 
 For analysis of ORF 50 and ORF 29 transcripts, cDNA was synthesized from 1 µg of 
RNA using SuperScript III (Life Technologies) and random hexamers (Life Technologies) as 
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described (35). qPCR was performed using Power SYBR Green Master Mix (Applied 
Biosystems) and the following primer sequences: 5'-TGCCCCCATGTTTGTGATG-3' and 5'-
TGTGGTCATGAGCCCTTCC-3' for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
(15), 5'-GATTCCCCTTCAGCCGATAAG-3' and 5'-CAGACATTGTAGAAGTTCAGGTC-3' 
for spliced ORF 50 transcript, and 5'- TTCTCATTGGCA TCTTTGAGG-3' and 5'- 
GGAAAATGGGGTGATCCTGT-3' for spliced ORF 29 transcript (35) on the StepOnePlus 
System (Life Technologies). Transcript levels were normalized to GAPDH within each sample 
and compared to untransfected cells using the ∆∆Ct method, where Ct is the threshold cycle (38). 
 
2.5.11 Statistical analysis. 
 Data were analyzed statistically with Prism 6 software (GraphPad Software, La Jolla, 
CA). All experimental conditions were compared to the corresponding untransfected or GFP 
ASO transfected controls as noted. Data were analyzed by two-tailed paired t-test or one-way 
ANOVA as indicated. All significant differences are noted. 
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Figure 2.1: An antisense oligonucleotide to ORF 6 decreases ORF 6 transcript and protein 
expression and late gene expression. 3T12 cells transfected with ASOs targeting ORF 6, M3, 
or GFP (negative control) or left untransfected (No ASO) were infected with MHV68. (A) 
Representative northern blot for ORF 6 or actin transcripts at 14 hpi and corresponding 
quantification of ORF 6 monocistronic transcript levels normalized to those of actin (MOI=10, 
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mean +/- S.E.M., 3 experiments, ** p<0.01 by paired t-test). (B) Representative western blot for 
ORF 6 and actin protein at 18 hpi and corresponding quantification of ORF 6 normalized to actin 
(MOI=10, mean +/- S.E.M., 8 experiments, *** p<0.001 by paired t-test). Relevant lanes of 
representative blots are shown. (C) Flow cytometry analysis of ORF 4 surface expression at 24 
hpi (MOI= 5 or 10). Flow cytometry data are graphed as the percentage of ORF 4 positive cells 
for each condition normalized to the value from untransfected cells (mean of 34-35 replicates +/- 
S.E.M, statistically significant results relative to GFP are indicated, **** p<0.0001 by one-way 
ANOVA with Dunnett’s post-test). (D) Western blot analysis of M9 or ORF 26 at 18 hpi. 
Relevant lanes of representative blots are shown. Data are representative of four independent 
experiments. 
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Figure 2.2: Targeting of EGRs 9, 16, 18, 23, 26, and 27 reduces ORF4 surface expression on 
infected cells. 3T12 cells transfected with the indicated ASOs or left untransfected were 
analyzed for cell surface expression of ORF 4 at 24 hpi by flow cytometry. Cells were infected at 
MOI = 5 or 10. Controls were included in parallel in each experiment in which EGRs were 
analyzed. The percentage of ORF 4 positive cells for each condition was normalized to the value 
from untransfected cells. Data are presented as mean of the pooled data +/- S.E.M; n=number of 
independent experiments. Statistically significant results relative to GFP are shown. * p<0.05; ** 
p<0.01; *** p<0.001; ****p<0.0001 by one-way ANOVA with Dunnett’s post-test. Black bars: 
controls (data reproduced from Fig. 2.1C); gray bars: EGRs. 
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Figure 2.3: EGR 26 - 27 transcriptional architecture. (A) Schematic representation of EGR 
26-27/M9 region transcripts. Approximate size and transcript name are listed below the relevant 
transcript. (B) Northern blot detection of EGR 26-27/M9 region transcripts. RNA harvested at 18 
hpi (MOI=10) was analyzed by northern blot analysis using the indicated probes. 28S and 18S 
rRNA bands visualized by ethidium bromide staining to demonstrate equal loading are shown 
below the corresponding northern blots. Northern blots analyzed with probe 12 and probe 2 (at 
far right of panel) had 500 ng of polyA-selected RNA per lane. * indicates virus-specific bands 
that are of comparable size to EGR 27 transcripts A and B. ** indicates smaller EGR 26 
transcripts referenced in text. 
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Figure 2.4: EGR 26 and 27 transcripts are enriched in nucleus of infected cells. Protein or 
RNA extracted from nuclear or cytoplasmic fractions or unfractionated cells (Total) was 
analyzed by western blot (A) or northern blot (B) at 18 hpi (MOI=10). (A) 4 μg of protein was 
loaded per sample. (B) 5 μg of RNA for each total sample and approximate cellular equivalents 
for nuclear (0.5 μg) or cytoplasmic (4.5 μg) fractions were analyzed. Data are representative of 
three independent experiments. EGR 26-A indicates EGR 26 transcript A (as shown in Fig. 2.3) 
detected using northern blot probe 2. EGR 27-A indicates EGR 27 transcript A and EGR 27-B 
indicates EGR 27 transcript B (as shown in Fig. 2.3) detected using northern blot probe 11. 
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Figure 2.5: Effect of targeting EGR 26 and EGR 27 transcripts on ORF 4 surface 
expression. (A) Schematic of EGR 26-27 region. See Table 2.1 for specific coordinates targeted 
by ASOs. (B-D) 3T12 cells transfected with the indicated ASOs were analyzed for EGR 27 
transcript A (B), EGR 27 transcript B (C), or EGR 26 transcript A (D) at 14 hpi by northern blot. 
EGR 27 transcripts A and B were detected using northern blot probe 11 and EGR 26 transcript A 
was detected using northern blot probe 2. Depending on the experiment, 1.5 – 5 μg RNA was 
used per sample. The graphs are quantitation of signal intensity of the indicated transcript 
normalized to actin and presented as a fraction of the signal from untransfected cells. 
Representative northern blots are shown. The actin for EGR 27 transcripts is reproduced for 
panels B and C as the same blot is displayed. # indicates the location of a tear in the agarose gel. 
Data are presented as mean of the pooled data (3-7 experiments) +/- S.E.M. (E) 3T12 cells 
transfected with the indicated ASOs were analyzed for cell surface expression of ORF4 at 24 hpi 
by flow cytometry. As in Figure 2.2, the percentage of ORF4 positive cells for each condition 
was normalized to the value from untransfected cells. Data are presented as mean of the pooled 
data (5-35 experiments) +/- S.E.M. (F) 3T12 cells transfected with the indicated ASOs were 
analyzed for viral titer at 24 hpi by plaque assay. Data are presented as mean (3 experiments) +/- 
S.E.M. Statistically significant results relative to GFP are shown (* p<0.05; ** p<0.01; *** 
p<0.001; **** p<0.0001 by one-way ANOVA with Dunnett’s post-test). Black bars: controls; 
gray bars: EGR 26-27 ASOs.  
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Figure 2.6: Effect on immediate-early, early, and late genes by EGR27. 3T12 cells 
transfected with GFP or ASOs targeting EGR 27 or left untransfected (No ASO) were infected 
with MHV68 (MOI=10) and analyzed for protein (A and D) or transcript levels (B-C and E). See 
figure 2.5 and Table 2.1 for ASO locations. (A) Representative western blot for M9 and ORF 26 
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proteins at 18 hpi (2-3 experiments). (B) ORF 29 transcript levels at 14 hpi. 1 μg RNA was 
reverse transcribed (RT) and cDNA was analyzed by qPCR using primers designed to detect 
spliced ORF 29 transcripts or GAPDH. Data are presented as relative ORF 29 abundance 
normalized to GAPDH and compared to untransfected cells by the ∆∆Ct method (mean +/- 
S.E.M.; 3-8 experiments). (C) Representative northern blot for ORF 6 and actin at 14 hpi and 
corresponding quantification of ORF 6 transcript levels normalized to actin and compared to the 
value in untransfected cells (mean +/- S.E.M., 5-7 experiments). (D) Representative western blot 
for ORF 6 and actin at 18 hpi (3 experiments). The representative experiment is the same as 
shown in (A). (E) ORF 50 transcript levels at 14 hpi measured by qRT-PCR as in (B). Statistical 
analyses were performed by one-way ANOVA with Dunnett’s post-test. * p<0.05; ** p<0.01; 
*** p<0.001; **** p<0.0001; ns = not significant. 
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Figure 2.7: EGR 26c ASO decreases specific genes of all kinetic classes. 3T12 cells 
transfected with GFP or EGR 26c ASO or untransfected (No ASO) were infected with MHV68 
(MOI=10) and analyzed for protein (A, C, and E) or transcript levels (B, D and F). (A) 
Representative western blots for M9 and actin at 18 hpi (2 experiments). (B) Representative 
northern blot using a probe to M3 or actin at 14 hpi and corresponding quantification of M3 
transcript levels normalized to those of actin (mean +/- S.E.M., 3 experiments). 0.5 μg RNA was 
used per lane for M3 northern blot. (C) Representative western blot for M3 protein at 18 hpi and 
corresponding quantification of M3 protein levels normalized to those of actin (mean +/- S.E.M., 
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4 experiments). (D) Representative northern blot for ORF 6 and actin at 14 hpi and 
corresponding quantification of ORF 6 transcript levels normalized to actin for cells transfected 
with GFP or EGR 26a-f ASOs (mean +/- S.E.M., 3-5 experiments). (E) Representative western 
blot for ORF 6 and actin at 18 hpi and corresponding quantification of ORF 6 protein normalized 
to actin (mean +/- S.E.M., 5 experiments). Representative western blots for ORF 6 are the same 
as presented in figure 2.1. (F) ORF 50 transcript levels at 14 hpi. 1 μg RNA was reverse 
transcribed and cDNA was analyzed by qPCR using primers designed to detect spliced ORF 50 
transcripts or GAPDH. Data are presented as relative ORF 50 abundance normalized to GAPDH 
and compared to untransfected cells by the ∆∆Ct method (mean +/- S.E.M.; 4 experiments). 
Statistical analyses were performed by paired t-test (A-C and E) or one-way ANOVA with 
Dunnett’s post-test (D and F). * p<0.05; ** p<0.01; *** p<0.001; ns = not significant. 
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Figure 2.8: Genome-wide RNA expression in MHV-68 as detected by RNA-Seq.  RNA-Seq 
RNA expression measurements are highly reproducible, strongly correlate with our earlier tiled 
array results, and confirmed the expression of all 30 expressed genomic regions (EGRs). 
Transcriptional signal from infected 3T12 cells at 18 hpi was plotted on a log2 scale underneath 
the annotated gene positions. Read depth from two independent RNA-Seq experiments was 
plotted, on a log2 scale, as blue/light blue and red/light red lines for the positive and negative 
genomic strands, respectively. Blue or red arrows represent annotated genes on the positive or 
negative strand of the genome, respectively. Gray boxes represent the two internal repeat regions 
of the MHV-68 genome that were excluded from our analysis. EGRs 1-30 are shown as hatched 
arrows.  (A) Genomic positions 1-40 kb. (B) Genomic positions 40-80 kb. (C) Genomic 
positions 80-119.45 kb.
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Table 2.1: Antisense oligonucleotide probes 
Probe Name Sequence (5'-3') Start Position End Position 
Target 
Strand1 
as-GFP GGAGGTGTGGGAGGTT       
as-ORF 6 CCCCCAACAGCCTTTC 12242 12257 + 
as-M3 CTCCACACCAGGTAAA  6617 6632 - 
as-EGR 9a CTTCCCCTGCACCCCT 28561 28576 + 
as-EGR 9b CTCAGTCCGCCATCAT 29191 29206 + 
as-EGR 10a ATACGCTATCCTCGAC 30044 30059 - 
as-EGR 10b TTGATTCTGGCTGGTT 30529 30544 - 
as-EGR 11a ACCATGCGAGACATCA 30812 30827 + 
as-EGR 11b AGAACTGCTAGGGAAT 31578 31593 + 
as-EGR 15 AGAGACAAGACTGGAA 46703 46718 + 
as-EGR 16 ACCAGCCTTTTTGATT 50819 50834 + 
as-EGR 18a AACTGGTGTTGTTCTA 56313 56328 + 
as-EGR 18b ATTTCTAGCAGCCTTT 56450 56465 + 
as-EGR 20 GAATAGCACGCAACGA 60121 60136 - 
as-EGR 21 TAGACCAGGATATGAC 62546 62561 - 
as-EGR 23a ACACAATACCACTGAA 68533 68548 - 
as-EGR 23b CCCTTCTTCCGCCACA 68704 68719 - 
as-EGR 23c CCAATCACCCACTCCC 69268 69283 - 
as-EGR 23d AACAGAGACGCCAGAT 70737 70752 - 
as-EGR 25 TCTACTGCTGTCTAAC 74083 74098 - 
as-EGR 26a CCTCCAGTGGACAGAT 85876 85891 - 
as-EGR 26b AAACCTTCTGCCATGA 85596 85611 - 
as-EGR 26c2 ACATCATCAACGGGAC 85576 85591 - 
as-EGR 26d ACTTATCCTACGAGCC 85357 85372 - 
as-EGR 26e CATTGTCCTCATCACC 85256 85271 - 
as-EGR 26f ACACACTGATGCTCGT 85006 85021 - 
as-EGR 27a TGTCTGCTTAGCTGTT 98843 98858 - 
as-EGR 27b2 GCACGAGTCCTACCTT  98705 98720 - 
as-EGR 27c TACCATGCGCTCAACA 98057 98072 - 
as-EGR 27d AACTACGCTCACCACT 98004 98019 - 
as-EGR 30 CGACCACTTCCTCATT 116835 116850 + 
 
1assuming genome orientation as in (25, 58). 
2EGR 26 and 27 ASOs used in screen (Fig. 2.2). 
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Table 2.2: PCR primers for northern blot probes 
Target 
Gene 
Probe 
Name 
Orientati
on Primer Sequence (5'-3')1 
EGR 26 Probe 1 Forward ATTTAGGTGACACTATAGAACTGTTCGCTTGATCTCTGACGC 
    Reverse TAATACGACTCACTATAGGGCCCAATAGCTGGACATCTCCCC 
EGR 26  Probe 3 Forward ATTTAGGTGACACTATAGAAAGGCCGGAGTAAAGTCAGC 
    Reverse TAATACGACTCACTATAGGGGCTACAGAAAATAAACATCAGGACC 
EGR 26 Probe 4 Forward ATTTAGGTGACACTATAGAACTTGAAAGTAGTGGTGTGCGGG 
    Reverse TAATACGACTCACTATAGGGCCATGTCCAGGCCAAAGTATGC 
EGR 26  Probe 5 Forward ATTTAGGTGACACTATAGAAAATATCCCCCAGACCAGCATCG 
    Reverse TAATACGACTCACTATAGGGACCGCATATCAATTCCACACGC 
EGR 26 Probe 6 Forward ATTTAGGTGACACTATAGAACCTTGTCCCTAGAGGTGTCTGG 
    Reverse TAATACGACTCACTATAGGGATATCCAAAGCTCGACCCCAGG 
EGR 27 Probe 8 Forward ATTTAGGTGACACTATAGAATGTGTCTGGCTCGGAGTAATCG 
    Reverse TAATACGACTCACTATAGGGTATGCGACCCTCTGCTTCTACG 
EGR 27 Probe 9 Forward ATTTAGGTGACACTATAGAACGGGTCTGGACGTACATAAGGG 
    Reverse TAATACGACTCACTATAGGGCCTGTCAGTTGGCACAGTTTCC 
EGR 27 Probe 10 Forward ATTTAGGTGACACTATAGAAAAGATCTCCCCACACTGTCC 
    Reverse TAATACGACTCACTATAGGGATCTCAAGAATATCGCGCCAGG 
  Probe 11 Forward ATTTAGGTGACACTATAGAACAAGAGGCTTTGACATCGTCCC 
    Reverse TAATACGACTCACTATAGGGGCTGTCAGAAACAGCCTGACC 
  Probe 12 N/A 
GCTACTGGACGGACCTCTGCTGTGCTGCTCCTCGCTTTGCCTGTCT
C 
  Probe 13 Forward ATTTAGGTGACACTATAGAACATCCTACGTCATCAAGCAGCG 
    Reverse TAATACGACTCACTATAGGGTGCCAACTATCCACACCCTACC 
ORF 6 ORF 62 Forward ATTTAGGTGACACTATAGAAACATATCCTGCAGAAAACTGCG 
    Reverse TAATACGACTCACTATAGGGCAGTCCATGCTGCATATAGTA 
M3 M3 Forward ATTTAGGTGACACTATAGAAAGATTGCCATTCCCCTCTGTGG 
    Reverse TAATACGACTCACTATAGGGTGGCACTCAAACTTGGTTGTGG 
Neat2 Neat23 Forward ATTTAGGTGACACTATAGAAGTTACCAGCCCAAACCTCAA 
    Reverse TAATACGACTCACTATAGGGCTACATTCCCACCCAGCACT 
 
1Sp6 and T7 promoter sequences are underlined. 
2adapted from (27). 
3adapted from (23). 
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Table 2.3: 3' ends of MHV68 transcripts identified by RNA sequencing. The average number 
of reads per position at 6 hpi and 18 hpi is indicated in bold in the 2nd and 3rd columns, 
respectively. The numbers in parentheses indicate the number of reads from specific experiments 
at the indicated time point. The numbers in parentheses indicate the number of reads detected in 
individual experiments at the indicated time point. Gene region refers to a possible gene 
associated with the indicated polyadenylation site selected based on the gene with the closest 3' 
end to a given site. 
Position 
Number of 
Reads  
at 6 hpi 
Number of 
Reads  
at 18 hpi Strand Gene Region 
3378 0 84 (124, 45) - M2 
6007 678 (1030, 326) 328 (297, 359) - M3 
9866 246 (315, 178) 104 (44, 163) + M4 
14909 424 (534, 315) 300 (314, 287) + ORF 6 
19123 49 (64, 34) 848 (836, 861) + ORF 8 
23293 14 (18, 9) 14 (2, 25) + ORF 10 
24698 192 (272, 113) 109 (80, 138) + ORF 11 
24698 28 (41, 15) 71 (25, 117) - K3 
28264 348 (527, 169) 777 (588, 966) - ORF 17 
30458 18 (25, 12) 0 + ORF 18b 
30700 136 (213, 59) 86 (40, 133) - ORF 19 
30785 322 (529, 114) 102 (80, 125) + ORF 18b 
34847 142 (203, 80) 78 (18, 138) + ORF 21 
34959 36 (51, 21) 31 (9, 53) + ORF 21 
35524 10 (17, 4) 34 (18, 51) + ORF 21 
36936 0 28 (18, 39) + ORF 22 
36936 39 (60, 18) 228 (195, 260) - ORF 23 
37023 68 (93, 44) 119 (99, 139) + ORF 22 
37029 0 6 (6, 6) - ORF 23 
39039 6 (6, 5) 6 (6, 6) + EGR 13 
44726 0 14 (3, 24) + ORF 25 
45541 0 15 (11, 19) + ORF 26 
46402 30 (36, 24) 254 (191, 317) + ORF 28 
49667 0 18 (11, 26) + ORF 32 
50905 22 (22, 21) 46 (47, 44) + EGR 16 
55759 0 11 (15, 7) + ORF 37 
55775 82 (110, 55) 
7769 (9263, 
6275) - ORF 39 
55815 0 102 (63, 142) + ORF 38 
58881 5 (6, 4) 0 + ORF 40 
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Table 2.3 (cont): 3' ends of MHV68 transcripts identified by RNA sequencing 
Position 
Number of Reads 
at 6 hpi 
Number of Reads 
at 18 hpi Strand Gene Region 
63621 104 (137, 71) 612 (679, 544) - ORF 45 
65405 45 (57, 33) 164 (161, 166) - ORF 48 
66116 5 (5, 5) 0 - ORF 49 
69462 8 (10, 7) 40 (11, 70) + ORF 50 
70937 206 (303, 109) 2544 (1775, 3313) - ORF 52 
70938 38 (56, 19) 230 (217, 243) + M7 
71293 0 10 (10, 10) - ORF 53-2 
72561 16 (25, 6) 40 (17, 62) - ORF 55 
72764 52 (69, 35) 18 (2, 34) + ORF 54 
76559 6 (7, 4) 0 + M8 
76613 4 (7, 2) 12 (10, 15) + M8 
76801 18 (26, 11) 0 + M8 
77186 0 100 (96, 104) - ORF 58 
77187 86 (107, 66) 62 (19, 105) + ORF 57 
77192 114 (152, 77) 0 - ORF 58 
77922 784 (1099, 468) 374 (240, 509) - ORF 59 
80483 801 (998, 604) 214 (146, 283) - ORF 61 
85207 25 (26, 24) 956 (1437, 475) - EGR 26 
93842 528 (664, 391) 6305 (5254, 7356) - M9 
93938 16 (24, 9) 14 (10, 17) + ORF 64 
95322 30 (38, 22) 54 (39, 69) - ORF 67 
95758 0 5 (6, 4) - ORF 67 
95895 5 (6, 4) 0 - ORF 67 
98510 148 (233, 63) 260 (109, 410) - EGR 27 
98953 43 (59, 27) 190 (115, 266) + ORF 69 
102412 0 17 (8, 26) - ORF 72 
103787 10 (11, 8) 4 (3, 6) - ORF 73 
105812 216 (296, 136) 849 (672, 1026) - ORF 75c 
106644 5 (8, 2) 56 (63, 49) + ORF 74 
117906 0 16 (9, 23) + EGR 30 
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Chapter 3: 
Stat1 regulates transcription of the murine 
gammaherpesvirus 68 latent-to-lytic switch gene, ORF 50 
 
 
 
 
 
 
 
 
In addition to unpublished data, portions of this chapter are adapted from: 
Goodwin MM, Canny S, Steed A, Virgin HW. Murine gammaherpesvirus 68 has evolved 
gamma interferon and STAT1-repressible promoters for the lytic switch gene 50. Journal of 
Virology. 2010. 84(7): 3711-7.
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3.1 Abstract 
 Interferons (IFN) are critical regulators of chronic murine gammaherpesvirus 68 
infection, suppress reactivation from latency, and are elevated in the serum of latently infected 
mice. In this chapter, we defined a role for IFNγ and Stat1 in suppressing viral replication in 
bone marrow-derived macrophages and transcription of the latent-to-lytic switch gene, ORF50. 
We found that IFNγ decreased activity of the two known ORF 50 promoters and identified a role 
of the key IFN signaling molecule, Stat1, in regulating the promoters of the latent-to-lytic switch 
gene, ORF 50. The suppressive activity of IFNγ was independent of canonical Stat binding sites. 
Promoter studies in Stat1-, IFNβ- and IFNα/βR-deficient macrophages in the absence of IFNγ 
suggested that type I IFNs also repressed ORF 50 promoter activity. Together, these data suggest 
that gammaherpesvirus 68 ORF 50 promoters have evolved elements responsive to Stat1 to 
control the transition between lytic and latent life cycles.
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3.2 Introduction 
Herpesviruses undergo acute infection followed by the establishment of a life-long latent 
infection during which the virus can periodically reactivate. Lytic gene expression following 
reactivation is thought to be an important component of pathology caused by herpesviruses (16, 
21, 37, 46, 47). Both host and viral factors are critical for control of viral latency and 
reactivation. Murine gammaherpesvirus 68 (MHV68, γHV-68, MuHV4) is a rodent virus that 
provides a tractable model system for the oncogenic human gammaherpesviruses, Epstein-Barr 
Virus (EBV) and Kaposi's sarcoma associated herpesvirus (KSHV). Type I interferons (IFNs) 
are important to control acute MHV68 infection; infection of IFNα/βR-/- mice leads to elevated 
viral titers in the lungs and dose-dependent mortality (14). While IFNγ is dispensable for control 
of acute MHV68 infection in C57BL/6 mice, it is required in BALB/c mice; IFNγR-/- mice on 
the BALB/c background succumb to an acute bronchopneumonia (30, 49). For MHV68, both 
type I and type II interferons (IFNs) are essential for regulating reactivation from latency, 
whereas type II (IFNγ), but not type I, IFNs are important for controlling persistent viral 
replication and MHV68-induced vasculitis (1, 10, 15, 51, 54, 59). 
While both type I and type II IFNs can signal through STAT1, type I IFNs can also 
activate STAT2, STAT3, and STAT5 to form homodimers or heterodimers (reviewed in (43)). 
Classically, type I IFNs induce STAT1-STAT2 heterodimers which form a complex with 
interferon regulatory factor (IRF) 9 and binds to IFN-stimulated response elements (ISRE) 
(reviewed in (43)). IFNγ signaling induces STAT1 phosphorylation, dimerization of STAT1 and 
translocation to the nucleus to transactivate promoter elements (44). The tyrosine at position 701 
is required for STAT1 phosphorylation and dimerization (50). IFNγ activation of gene 
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transcription is primarily mediated by STAT1 homodimers binding to IFNγ-activated site (GAS) 
elements (11). Type I IFN-stimulated complexes can also bind to GAS elements (43). 
The main effectors of type I IFNs are IRF3 and IRF7 (reviewed in (23)). Interestingly, 
IRF3 and IRF7 have been found to interact with gammaherpesvirus proteins. KSHV vIRF3, 
EBV BGLF4, and MHV68 ORF 36 all bind cellular IRF3 (24, 35, 56). IRF7 interacts with and 
regulates EBV proteins, LMP-1 and EBNA-1, as well as KSHV ORF 57 transactivation by RTA 
(40, 57, 66, 67). Interestingly, IRF7 is also targeted for degradation by RTA, suggesting that 
tight control of its levels during gammaherpesvirus infection is important (64). The key effectors 
of IFNγ are IRF1 and CIITA (reviewed in (3)). KSHV encodes a vIRF1 which inhibits type I 
IFN and acetyltransferase activity (6, 31, 32). Less is known about how IFNs and STAT1 
suppress gene transcription. 
 The molecular mechanism by which IFNγ controls viral replication and reactivation is 
unknown. We found that IFNγ could suppress viral replication of MHV68 in macrophages in 
vitro and reduced the abundance of transcripts of the key latent-to-lytic switch gene, ORF 50, 
which is essential for viral replication (17, 42). IFNγ –mediated suppression of viral replication 
in macrophages was dependent on its receptor and Stat1, but was independent of Irf1, CIITA, 
Irf3 and Irf7 (17). To determine whether IFNγ reduced ORF 50 transcript levels by acting 
directly on the known promoters, we evaluated ORF 50 promoter activity by luciferase assay in 
the presence of varying doses of IFNγ. We found that IFNγ regulated promoter activity of the 
known ORF 50 promoters in a dose- and Stat1-dependent manner, but that predicted GAS 
elements in the ORF 50 promoters were dispensable. We also identified a role for Stat1 in the 
regulation of ORF 50 promoter activity in the absence of IFNγ. This activity was dependent on 
the IFNα/β receptor and IFNβ cytokine, suggesting a role for type I IFNs in controlling ORF 50 
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promoter activity and viral replication in macrophages. Taken together, these results demonstrate 
a molecular mechanism by which IFNγ and type I IFNs control ORF 50 gene expression and 
suggest that the virus has maintained Stat1-repressible elements perhaps to aid in the delicate 
balance necessary to preserve chronic infection in a long-lived host.
83 
 
3.3 Results 
3.3.1 IFNγ suppresses viral replication in bone marrow-derived macrophages. 
 To determine the role of IFNγ in regulating viral replication in macrophages, we infected 
bone marrow-derived macrophages from wild-type C57BL/6 mice as well as mice deficient in 
various IFN signaling molecules in the presence or absence of IFNγ and assessed viral growth at 
various times post infection. IFNγ significantly inhibited viral replication at 24 hours post 
infection (hpi), 48 hpi and 72 hpi (Fig. 3.1). As expected, IFNγ-mediated suppression of viral 
replication was dependent on its receptor and the key signaling molecule, Stat1. IFNγ-mediated 
suppression of viral replication was independent of the type II IFN effectors, Irf1 or CIITA, as 
well as the IFNα/βR and the type I IFN effectors, Irf3 or Irf7 (Fig. 3.1). 
 
3.3.2 Phosphorylation of Stat1 is required for IFNγ-mediated suppression of viral 
replication in bone marrow-derived macrophages. 
 To determine whether phosphorylation of Stat1 was necessary for IFNγ to regulate viral 
replication, we evaluated the effect of IFNγ on viral replication in bone marrow macrophages 
derived from mice in which the tyrosine at position 701 in Stat1 was mutated to a phenylalanine 
(Y701F). IFNγ was unable to suppress viral replication in these cells (Fig. 3.2), suggesting that 
canonical IFNγ signaling, involving Stat1 phosphorylation and dimerization, is required to 
regulate viral replication. 
 
3.3.3 IFNγ-mediated regulation of ORF 50 transcript levels is dependent on Stat1. 
 To determine whether IFNγ regulated the lytic switch gene RTA encoded by ORF 50, we 
evaluated ORF 50 transcript levels by quantitative reverse transcription-PCR (qRT-PCR) at 12 
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hpi, a time point at which no difference in viral titer was observed in the presence or absence of 
IFNγ (Fig. 3.1). ORF 50 transcript levels were significantly reduced by IFNγ at 12 hpi (Fig. 
3.3A). Importantly, ORF 73 transcript levels were unchanged in the presence of IFNγ, 
suggesting that early events in virus binding and entry were unaffected by IFNγ treatment (Fig. 
3.3B). As expected, IFNγ-mediated suppression of ORF 50 RNA was dependent on Stat1 (Fig. 
3.3A). Moreover, in the absence of IFNγ, ORF 50 transcript levels were elevated in Stat1-
deficient macrophages, suggesting a role for Stat1 in basal or IFNα/β-mediated regulation of 
ORF 50 transcript expression (Fig. 3.3A). 
 
3.3.4 IFNγ suppresses ORF 50 promoter activity. 
 To determine whether IFNγ regulates ORF 50 transcript levels by acting directly on ORF 
50 promoters, we assessed the activity of the known ORF 50 promoters in the presence of IFNγ 
using a luciferase assay. We found that IFNγ reduced promoter activity of the two known 
promoters, a 410 bp promoter for the primary ORF 50 transcript (33) and a 250 bp promoter for 
an alternative ORF 50 transcript (20) in a dose dependent fashion (Fig. 3.4). At 10 units/ml, IFNγ 
decreased the 410 bp promoter activity ~32-fold and the 250 bp promoter ~15-fold. These data 
suggest that IFNγ regulated ORF 50 expression by directly suppressing its promoters. 
 
3.3.5 Stat1 is required for IFNγ-mediated regulation of ORF 50 promoter activity. 
 Much of the activity of IFNγ is mediated by Stat1 signaling (44). To determine whether 
Stat1 was required for IFNγ-mediated suppression of ORF 50 promoter activity, we evaluated 
ORF 50 promoter activity in Stat1-deficienct macrophages in the presence or absence of IFNγ. 
We found that IFNγ did not suppress the activity of either ORF 50 promoters in Stat1-deficient 
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macrophages, demonstrating that Stat1 was necessary for IFNγ to suppress ORF 50 promoter 
activity (Fig. 3.5A-B). 
 
3.3.6 IFNγ-mediated suppression of ORF 50 promoter activity is independent of 
predicted GAS elements. 
 We used MatInspector to predict potential Stat1 binding elements within the ORF 50 
promoters (Fig. 3.6A). To determine whether these predicted elements in the ORF 50 promoters 
were necessary for IFNγ's action, we assessed ORF 50 promoter activity in luciferase vectors in 
which we had mutated these elements to sequences known to disrupt Stat1 binding (12, 19, 27). 
We found that IFNγ suppressed ORF 50 promoter activity even when GAS elements were 
mutated (Fig. 3.6B-C). To define the location of IFNγ responsive elements in the core ORF50 
promoter, we used luciferase reporter constructs containing fragments of the 410 bp ORF50 
promoter (33). We found that IFNγ responsive elements in the 410 bp ORF50 promoter resided 
within the minimal promoter region contained within nucleotides 66442 – 66552 (Fig. 3.6D). 
These results suggest that IFNγ mediated its suppressive effect on ORF 50 promoter activity 
through potentially novel Stat1 binding elements or via an additional transcription factor. 
 
3.3.7 IFNγ-independent role for Stat1 in ORF 50 promoter activity. 
 In addition to the role of Stat1 in IFNγ-mediated suppression of ORF 50 promoter 
activity, we observed that ORF 50 promoter activity was elevated in Stat1-deficient macrophages 
(Fig. 3.7). To determine whether the role of Stat1 in modulating ORF 50 promoter activity in the 
absence of IFNγ was due to type I IFN signaling or basal regulation by Stat1, we assessed ORF 
50 promoter activity in macrophages deficient in the IFNα/β receptor (IFNα/βR) or the cytokine, 
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IFNβ. ORF 50 promoter activity was enhanced in macrophages deficient in Stat1, IFNα/βR, or 
IFNβ compared to wild type macrophages (Fig 7), suggesting that Stat1 regulation of ORF 50 
promoter activity in the absence of IFNγ was due to type I IFN signaling. 
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3.4 Discussion 
 In this chapter, we describe the role of Stat1 in controlling ORF 50 expression. We found 
that Stat1 was required to control ORF 50 promoter activity in both the presence and absence of 
IFNγ. The suppressive activity of IFNγ in macrophages was dependent on Stat1 phosphorylation, 
but not predicted GAS elements within ORF 50 promoters. These results indicate that Stat1 may 
regulate ORF 50 promoters by binding to a noncanonical motif or by inducing or repressing 
another host factor which in turn acts to suppress ORF 50 promoter activity. Stat1-mediated 
regulation of ORF 50 promoter activity in the absence of IFNγ was likely mediated through type 
I IFN signaling through Stat1 rather than a basal effect of Stat1. This finding has recently been 
confirmed by others (61). Taken together, these results provide a molecular mechanism for IFN-
mediated regulation of viral replication in vitro and suggest a mechanism for IFN-mediated 
control of viral reactivation in vivo. 
 
3.4.1 Regulation of ORF 50 Expression. 
 As the latent-to-lytic switch gene, it is important that ORF 50 expression be tightly 
controlled. MHV68 is unable to establish latency when ORF 50 is constitutively expressed by 
driving gene expression from a constitutively active promoter, suggesting that elements within 
the ORF 50 promoter are important in regulating the transition between latent and lytic infection 
(38). ORF 50 regulation has been best studied to date in KSHV. Known activators of ORF 50 
transcription include Oct-1, viral G protein-coupled receptor (ORF 74), XBP-1, HMGB1, 
Ras/MEF/ERK/Ets-1 pathway (4, 22, 48, 60, 63). Several known negative regulators of KSHV 
ORF 50 have also been identified: the transcription factors, NF-κB, RBP-Jκ, and YY1; cellular 
cohesins and the viral gene, latency-associated nuclear antigen (LANA), encoded by ORF 73 (5, 
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8, 9, 25, 28, 29). In MHV68, NF-κB inhibits lytic replication (5). We and others have identified a 
role for a complex of histone deacetylases (HDACs 3 and 4) with the nuclear receptor 
corepressor (NCoR) in regulating MHV68 ORF 50 expression (18, 62). Here, we have identified 
Stat1 as an additional negative regulator of MHV68 ORF 50 promoter activity. Whether there is 
any interaction between Stat1 and the HDAC-NCoR complex in ORF 50 regulation is currently 
unknown. 
Similar to MHV68, IFNγ is known to be important for controlling EBV infection. In case 
reports and small clinical studies, IFNγR deficiency or IFNγ polymorphisms that result in low 
production of IFNγ are associated with a range of EBV-associated malignancies, including 
nasopharyngeal carcinoma, post-transplant lymphoproliferative disease, B-cell non-Hodgkin 
lymphoma (2, 13, 55, 65). Interestingly, while IFNγ negatively regulates MHV68 ORF 50 
expression and lytic replication, this cytokine has been found to induce infectious virus 
production from latently infected KSHV BCBL-1 cells (7, 39). How IFNγ has opposing roles in 
regulating ORF 50 in KSHV and MHV68 and whether IFNγ induces replication of KSHV by 
acting on the ORF 50 promoters has not been studied to date. Our studies in MHV68 suggest that 
herpesviruses have evolved promoter elements responsive to inflammatory cytokines in order to 
control the delicate interchange between latent and lytic life cycles. 
 
3.4.2 Mechanisms of Stat1 regulation of MHV68. 
 We have demonstrated that Stat1 is a key molecule for IFN-mediated suppression of ORF 
50 expression. However, mutating putative Stat1 binding elements in the known ORF 50 
promoters did not alter IFNγ-dependent promoter activity. Similarly, IFNγ-mediated regulation 
of the bullous pemphigoid antigen gene was also found to be independent of GAS elements, but 
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dependent on ISRE and IRF consensus sequences in the gene's promoter (26, 41, 52). These 
results suggest that Stat1 suppression of ORF 50 expression may be mediated by noncanonical 
binding elements or via a second effector, altough IFNγ-dependent suppression of MHV68 
replication is independent of the classic effector genes, Irf1 and CIITA (3, 17). In contrast, for 
type I IFN regulation of ORF 50, a recent report has implicated the type I IFN transcription 
factor, Irf3, in mediating type I IFN-induced Stat1 regulation of ORF 50 transcription (61). 
 While IFNγ primarily induces gene transcription, there are several examples of genes that 
are repressed by IFNγ, including genes involved in regulation of extracellular matrix, cell cycle 
or chemokine signaling (44, 45). In one well-studied example, Stat1 represses promoter activity 
of matrix metalloproteinase 9 (MMP-9) by binding and sequestering the coactivator cyclic AMP 
response element-binding protein-binding protein (CREB-binding protein or CBP) and p300 
proteins (36). This results in reduced H3/H4 acetylation and RNA polymerase II recruitment to 
the promoter, thereby suppressing MMP-9 transcription (36). Whether Stat1 binds directly to the 
ORF 50 promoters through a novel inhibitory element or acts to sequester coactivators or recruit 
corepressors is unknown and will be the basis of future studies. 
 
3.4.3 Implications of Stat1 regulation of ORF 50 for viral pathogenesis. 
 The role of Stat1 in mediating suppression of ORF 50 promoter activity by both type I 
and type II IFNs suggests that ORF 50 promoters have evolved IFN responsive elements to 
control viral replication and establish the delicate balance necessary to maintain chronic infection 
in the face of an active immune response (17, 61). It is intriguing to speculate that such elements 
would be crucial to this function and if mutated, would result in a virus that maintains high levels 
of persistent viral replication and would be limited in its ability to establish and sustain a latent 
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infection. It may well be that the virus is benefited by maintaining elements responsive to 
immune regulation such that it can establish a latent infection that the immune system is unable 
to clear. Whether the virus maintains elements to respond to other immune signals to promote 
ORF 50 expression and viral reactivation is the basis of ongoing research. 
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3.5 Materials and Methods 
3.5.1 Cells, virus and viral assays 
 Primary bone marrow macrophages were derived as described (53) from C57BL/6, Stat1-
/-, Irf1-/-, Irf3-/-, Irf7-/-, CIITA-/-, IFNα/βR-/-, IFNβ-/-, 129, or Stat1 Y701F mice from internal 
breeding colonies at Washington University in St. Louis or purchased from Jackson Laboratory 
(Bar Harbor, ME). Mice were handled in accordance with federal and Washington University 
regulations. Cells were infected with MHV68 clone WUMS (ATCC VR-1465) for 1 hour at 
37ºC at a multiplicity of infection (MOI) of 10. Viral passage and titer were performed on NIH 
3T12 fibroblasts (ATCC CCL-164) as described (58) except that cells were overlaid with 2% 
methylcellulose in MEM supplemented with 5% FCS and 2 mM L-glutamine. 
 
3.5.2 Quantitative reverse transcriptase-PCR (qRT-PCR) 
 Total RNA was isolated 12 hpi using TRIzol reagent (Invitrogen, Carlsbad, CA) 
according to the manufacturer's instructions. RNA was treated with DNase I (Ambion, Austin, 
TX) before reverse transcription using oligo(dT)12-18 and Superscript II (Invitrogen, Carlsbad, 
CA). qRT-PCR was performed with SYBR green (Invitrogen, Carlsbad, CA) and the following 
primer sequences: 5′-TGCCCCCATGTTTGTGATG and 5′-TGTGGTCATGAGCCCTTCC for 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 5′-AGAAACCCACAGCTCGCACTT 
and 5′-CAATATGCTGGACAGGCGTATC for gene 50, and 5′-
CCAGAAGCTTGTGTACTTGTGGAT and 5′-AAATACCACAGCAGCGTAGAAGGT for 
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gene 73. Transcript levels were normalized to GAPDH within each sample and compared to 
untransfected cells using the ∆∆Ct method, where Ct is the threshold cycle (34). 
 
3.5.3 Reporter plasmids and transfections 
 DNA fragments of the 410 bp ORF50 promoter were cloned into the luciferase reporter 
vector, pGL2 (Promega, Madison, WI), as described previously (33). The 250 bp ORF50 
promoter described in (20) was cloned in to the pGL2 luciferase reporter vector. Point mutations 
were introduced to mutate predicted GAS sites using QuikChange site-directed mutagenesis 
(Stratagene, La Jolla, CA). Cesium chloride preparations of plasmids were transfected into bone 
marrow derived macrophages using an Amaxa Nucleofector II device (Lonza, Basel, CH). 
 
3.5.4 Luciferase promoter assay 
 1 x 106 bone marrow derived macrophages were incubated with IFNγ for 12 hours prior 
to co-transfection with 2 µg of the relevant pGL2 vector and 2 µg of pUB/V5-His/lacZ (Life 
Technologies, Grand Island, NY). Luciferase activity was measured at 12 hours post-transfection 
with the luciferase assay system (Promega) and normalized to β-galactosidase activity. The value 
from cells transfected with empty pGL2 vector was subtracted for each condition. 
 
3.5.5 Statistical analyses. 
 Data were analyzed statistically with Prism 5 software (GraphPad Software, La Jolla, 
CA). Data were analyzed by two-tailed t-test or one-way ANOVA with Dunnett's post-test as 
indicated. All significant differences are noted. 
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Figure 3.1: IFNγ-mediated suppression of lytic replication in bone marrow-derived 
macrophages is mediated by STAT1. Primary bone marrow-derived macrophages from the 
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indicated genotypes were incubated in the presence or absence of 10 units/ml of IFNγ for 12 
hours before infection with MHV68 (MOI = 10). After 1 hour of absorption, cells were washed 
and IFNγ was added back to treated cultures. At the indicated times postinfection, the viral titer 
was measured by plaque assay on 3T12 fibroblasts. The limit of detection was 50 plaque forming 
unit (PFU)/ml. Data were collected from 2-5 independent experiments and are presented as mean 
+/- standard error of the mean (SEM). Statistical analyses were performed by a Student’s t-test. 
*, p < 0.05; **, p < 0.01; ***, p< 0.001. Data generated by Dr. Megan Goodwin. 
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Figure 3.2: Stat1 Y701 residue is necessary for IFNγ-mediated suppression of lytic 
replication in bone marrow-derived macrophages. Bone marrow-derived macrophages from 
129 wild-type mice (A) or Stat1 Y701F mutant mice (B) were incubated in the presence or 
absence of 10 units/ml of IFNγ for 12 hours before infection with MHV68 (MOI = 10). After 1 
hour of absorption, cells were washed and IFNγ was added back to treated cultures. At the 
indicated times postinfection, the viral titer was measured by plaque assay on 3T12 fibroblasts. 
The limit of detection was 50 plaque forming unit (PFU)/ml. Data were collected from 2 
independent experiments and are presented as mean +/- SEM. Statistical analyses were 
performed by a Student’s t-test. *, p < 0.05. 
A 
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Figure 3.3: IFNγ suppresses MHV68 lytic switch gene 50 in a Stat1-dependent manner. (A) 
IFN-γ treatment decreased gene 50 transcript levels compared to medium alone in wild-type but 
not Stat1−/− bone marrow-derived macrophages. (B) In contrast, IFN-γ did not alter gene 73 
transcript levels. Day 10 bone marrow-derived macrophages were pretreated for 12 hours with 
10 units/ml of IFN-γ and then infected with MHV68 (MOI=10). Total RNA isolated 12 hours 
postinfection was reverse transcribed using oligo(dT)12-18 and Superscript II. ORF 50, ORF 73, 
and GAPDH transcript levels were determined by qRT-PCR. Transcript levels were normalized 
to GAPDH within each sample. Data were collected from 4 to 7 independent experiments and 
calculated using the ΔΔCT method. Data are presented as mean ± SEM, and statistical analyses 
were performed by a Student's t test. Data generated by Dr. Megan Goodwin. 
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Figure 3.4: IFNγ suppresses ORF 50 promoter activity. (A) Schematic of known ORF 50 
transcripts and their promoters. Transcription of the predominant ORF 50 transcript is driven by 
a 410bp promoter located at 66242-66652 in the MHV68 genome. Transcription of the ORF 50 
transcript including exon 0 is driven by a 250bp promoter located at 65667-65920. (B-C) Bone 
marrow derived macrophages from C56BL/6 mice were transiently transfected with 2 μg of a 
pGL2-luciferase vector containing the 410bp (B) or 250bp (C) ORF 50 promoter and 2 μg of a β-
galactosidase reporter drived by the ubiquitin promoter following pretreatment for 12 hours with 
varying doses of IFNγ. Luciferase assay was measured at 12 hours post-transfection and 
normalized to β-galactosidase expression, and the value from cells transfected with empty pGL2 
vector was subtracted for each condition. Data were pooled from 5 to 11 independent 
A 
B C 
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experiments and are presented as mean +/- standard error of mean (SEM). Statistical analyses 
were performed by a Student’s t-test. * p < 0.05; ** p < 0.01. RLU, relative light units; OD, 
optical density. 
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Figure 3.5: Stat1 is necessary for IFNγ-mediated suppression of ORF 50 promoter activity. 
(A-B) Bone marrow derived macrophages from Stat1-deficient mice were transiently transfected 
with 2 μg of a pGL2-luciferase vector containing the 410bp (A) or 250bp (B) ORF 50 promoter 
and 2 μg of a β-galactosidase reporter drived by the ubiquitin promoter following pretreatment 
for 12 hours with 10 units/ml of IFNγ. Luciferase assay was measured at 12 hours post-
transfection and normalized to β-galactosidase expression, and the value from cells transfected 
with empty pGL2 vector was subtracted for each condition. Data were pooled from 4 to 5 
independent experiments and are presented as mean +/- SEM. Statistical analyses were 
performed by a Student’s t-test. RLU, relative light units; OD, optical density. 
A B 
108 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B C 
D Reporter 
construct 
Genome 
coordinates 
1 66242-66652
2 66442-66552
3 66402-66552
4 66242-66552
 
Minimal promoter 
Predicted GAS Sites 
410bp Promoter 
nt 66356-66363  TTCTTGAA à  TCCTTGGA 
nt 66394-66403  TTCCCTGGAA à  TCCACTGGGA 
 
250bp Promoter 
nt 65686-65694  TTCCTTAAA à  TCCATTAGA 
A 
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Figure 3.6: IFNγ-mediated suppression of ORF 50 promoter activity is contained within the 
minimal 410bp promoter and does not require predicted Stat binding elements. (A) The 
nucleotide (nt) position and sequence of MatInspector-predicted GAS sites in the ORF 50 
promoters are listed. Bold, underlined nucleotides indicate nucleotides mutated to disrupt the 
predicted sites. (B-C) Bone marrow derived macrophages from C56BL/6 mice were transiently 
transfected with 2 μg of a pGL2-luciferase vector containing the 410bp (B and D) or 250bp (C) 
ORF 50 promoter or truncations of the 410bp promoter (D) and 2 μg of a β-galactosidase 
reporter drived by the ubiquitin promoter following pretreatment for 12 hours with varying doses 
(B-C) or 10 units/ml (D) of IFNγ. Luciferase assay was measured at 12 hours post-transfection 
and normalized to β-galactosidase expression, and the value from cells transfected with empty 
pGL2 vector was subtracted for each condition. Data were pooled from 3 to 8 independent 
experiments and are presented as means +/- SEM. Statistical analyses were performed by a 
Student’s t-test. *, p < 0.05; **, p < 0.01. RLU, relative light units; OD, optical density. 
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Figure 3.7: Stat1 regulates ORF 50 promoter activity in the absence of IFNγ. Bone marrow 
derived macrophages from C56BL/6, Stat1-/-, IFNβ-/- or IFNαβR-/- mice were transiently 
transfected with 2 μg of a pGL2-luciferase vector containing the 410bp (A) or 250bp (B) ORF 50 
promoter and 2 μg of a β-galactosidase reporter drived by the ubiquitin promoter. Luciferase 
assay was measured at 12 hours post-transfection and normalized to β-galactosidase expression, 
and the value from cells transfected with empty pGL2 vector was subtracted for each condition. 
Data were pooled from 3 to 4 independent experiments and are presented as means +/- SEM. 
Statistical analyses were performed by one-way analysis of variance (ANOVA) with Dunnett’s 
post-test compared to C57BL/6. *, p < 0.05; **, p < 0.01. RLU, relative light units; OD, optical 
density. 
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Chapter 4: 
Latent gammaherpesvirus 68 infection induces distinct 
transcriptional changes in different organs 
 
 
 
 
 
 
 
 
 
 
 
This chapter is adapted from: 
Canny SP*, Goel G*, Reese, TA, Zhang X, Xavier R, Virgin HW. Latent gammaherpesvirus 68 
infection induces distinct transcriptional changes in different organs. Journal of Virology. 2014. 
88 (1): 730-8. 
 *denotes equal contribution. 
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4.1 Abstract 
 Previous studies identified a role for latent herpesvirus infection in cross-protection to 
infection and exacerbation of chronic inflammatory diseases. To assess how latent viral infection 
alters host gene expression, we compared the transcriptional signature in spleens, livers, and 
brains from mice latently infected with gammaherpesvirus 68 to uninfected mice or mice 
infected with a virus that is defective in latency establishment. We identified over 600 genes that 
were differentially expressed in the tissues of latently infected mice and found distinct sets of 
genes linked to different pathways were altered in spleen compared to liver. Several of the most 
differentially expressed latency-specific genes (e.g. IFNγ, Cxcl9, Ccl5) are associated with 
known latency-specific phenotypes. 
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4.2 Text  
Herpesviruses transit between lytic and latent life cycles and cause lifelong infection of 
their hosts. Following acute lytic infection of various cell types, herpesviruses establish latency, 
defined experimentally as the presence of viral genome without production of infectious virus 
(23). Humans are chronically infected with numerous viruses, including several herpesviruses 
(23). However, the effect of chronic viral infection on the host is not well understood. We and 
others showed that latent viral infection can protect hosts from lethal challenges with bacteria 
and lymphoma cells (1, 25, 27). This latency-induced cross protection is associated with 
activation of macrophages, production of the inflammatory cytokine, interferon-gamma (IFNγ), 
and arming of natural killer cells (1, 25). Latent murine gammaherpesvirus 68 (MHV68, γHV-
68, MuHV-4) also modulates adenovirus and plasmodium infections (7, 13). MHV68 is 
implicated in exacerbating experimental autoimmune encephalomyelitis (EAE), a rodent model 
for multiple sclerosis (2, 14), as well as a mouse model of inflammatory bowel disease (12). 
Together, these studies are consistent with chronic or latent herpesvirus infection having 
substantial effects on host immune responses to unrelated antigens. This led us to determine 
whether latent herpesvirus infection induces distinct transcriptional changes in specific organs by 
analyzing microarray data from RNA extracted from spleens, livers, and brains of mice infected 
with MHV68 or a mutant MHV68 virus with a stop codon in open reading frame (ORF) 73 
(ORF73.stop) that undergoes acute replication, but is defective in the establishment of latency (5, 
11). 
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4.2.1 Chronic MHV68 alters the host transcriptional profile. 
To determine whether chronic MHV68 infection alters the host transcriptional profile in 
various organs, we infected 7-9 week old male C57BL/6J mice intranasally with wild-type (WT) 
MHV68, ORF73.stop mutant virus or mockulum (mock) as previously described (1). After 
cardiac perfusion with PBS to diminish tissue numbers of peripheral blood cells, brains, livers 
and spleens were harvested at 28 days post infection (dpi), a time point at which we know that 
latency is established and at which cross-protection to bacteria is apparent (1, 21, 25, 27). 
To identify the gene signature of latent infection, we analyzed the microarray data using 
two methods: (1) factorial analysis to identify genes with significant fold-change differences 
between WT MHV68 infected mice and ORF73.stop infected mice (after comparison of each to 
mock-infected mice) and (2) a two-way ANOVA to identify genes that were significantly 
differentially expressed due to type of tissue, virus, or the combination of these two factors (p-
value < 0.05 for reported genes in each analysis). Differential expression analysis was performed 
in MATLAB. For both analyses, differentially expressed genes were identified by first 
comparing mock-infected mice to mice infected with ORF73.stop or WT MHV68. Next, we 
compared the gene expression profiles of differentially expressed genes from mice infected with 
ORF73.stop virus to mice infected with WT MHV68 to identify a set of genes specifically 
differentially expressed in mice that were infected with the latency-sufficient WT MHV68. We 
considered this set of genes to be specific to latent infection. 604 genes were identified by both 
methods as differentially expressed in virus-infected hosts and we considered this our high 
confidence gene set (Fig. 4.1). Of these 604 genes, 601 genes were specifically differentially 
expressed in latently infected animals and 3 genes were specifically differentially expressed in 
ORF73.stop infected mice. 
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Some genes are regulated with oscillations in the circadian rhythm. In fact, a recent study 
delineated a role for the circadian clock in expression and function of an innate immune response 
gene, Toll-like receptor 9, highlighting the importance of controlling for diurnal gene regulation 
in studies of infection and immunity (17). Since two of the liver and spleen data sets were 
consistently collected in either the morning or afternoon, we included a third data set for which 
all samples were collected within two hours. We also computationally tested whether circadian 
rhythm genes were present in our list of genes regulated by latent infection. Only 3 of 67 genes 
related to circadian rhythm in MSigDB were present in our list of latency-specific host genes, 
indicating that time of harvest did not significantly confound our results. 
To confirm the reproducibility of the latency-specific differential gene expression that we 
observed, we compared our gene expression signature in the spleens of latently infected mice to 
a complementary data set of gene expression in spleens of latently infected mice, independently 
generated by another group (26). There were 309 genes in common between these two data sets 
(p-value = 1.8876e-24 by a hypergeometric test). Furthermore, we used a direct quantitative 
correlation computation to compare the data sets. Since the data sets were profiled on distinct 
platforms (Illumina vs Affymetrix), we identified the most similar probes on the two platforms 
using Smith-Waterman local alignment algorithm to compute a sequence nucleotide alignment 
score. After selecting matched pairs of probes, we evaluated the correlation between fold-change 
in expression as observed in the two data sets. The regression coefficient between the 
comparable sets of data was 0.67. Together, these analyses demonstrate a significant overlap 
between spleen data sets generated using distinct platforms at different institutions and indicate 
that the gene expression changes that we identified are robust. Our data extend these findings by 
analyzing gene expression in additional tissues, specifically liver and brain. 
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 To further validate our microarray findings, we selected 10 genes that we identified as 
specifically differentially expressed in latently infected animals to confirm by quantitative real-
time PCR (qRT-PCR, Fig. 4.2). Genes were selected to encompass a range of fold changes and 
differential expression patterns (some specific to spleen, some specific to liver and some 
differentially expressed in both tissues), and relationship to known pathways (e.g. IFNγ 
signaling) or diseases (e.g. genome wide association studies of multiple sclerosis or celiac 
disease) of interest. Our analyses predicted that basic leucine zipper transcription factor, ATF-
like (Batf), IFNγ, and interleukin 18 receptor accessory protein (Il18rap) were upregulated in the 
spleens of latently infected mice; vascular cell adhesion molecular 1 (Vcam1), spleen tyrosine 
kinase (Syk) and pleckstrin (Plek) were upregulated in the livers of latently infected mice; 
interferon gamma induced GTPase (Igtp), interferon inducible GTPase 1 (Iigp1), and guanylate 
binding protein 1 (Gbp1) were upregulated in both livers and spleens while macrophage receptor 
with collagenous structure (Marco) was upregulated in livers, but downregulated in spleens. We 
confirmed latency-specific differential expression for 7 of 10 genes and 14 of 18 predictions. We 
found that Gbp1, Igtp, Iigp1, Marco, Syk and Vcam1, but not Batf or Plek, were differentially 
expressed in the livers of latently infected mice and that Gbp1, IFNγ, Igtp, Iigp1, Marco, and 
Syk, but not Batf, Il18rap, Plek or Vcam1, were differentially expressed in the spleens of latently 
infected mice (Fig. 4.2). These results demonstrate that our computational analyses specifically 
identified many genes differentially expressed in latently infected animals. 
 To identify the genes with the largest differential gene expression in latently-infected 
animals, we calculated the signal-to-noise ratio for each gene in each tissue by determining the 
difference between the mean fold change of MHV68 vs. mock and ORF73.stop vs. mock scaled 
by the variance between these (i.e. the sum of the standard deviations). For genes detected by 
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multiple probes, we averaged the fold change across the probes and then computed the signal-to-
noise ratio using the average fold change values. Genes were ranked in order of the absolute 
value of the signal-to-noise ratio. We selected the top 50 genes identified in this signal-to-noise 
analysis and identified those that overlapped with the genes detected as statistically significant in 
our previous analyses. This conservative approach generated a set of genes (Tables 4.2-4.4) that 
exhibit infection-related changes in expression which we then used as a substrate for considering 
the biological pathways that might be altered by chronic viral infection in different organs. 
 
4.2.2 Distinct pathways are regulated by latent viral infection in livers and spleens. 
Using hierarchical clustering, we found that the differentially expressed genes covaried 
by organ (Fig. 4.1). We identified a subset of genes that were primarily differentially expressed 
in the liver and a separate subset of genes that were primarily differentially expressed in the 
spleen with modest overlap between the two tissues. To determine the specific cellular pathways 
altered in the organs of latently infected mice, we used MSigDB to evaluate pathway enrichment 
by Gene Set Enrichment Analysis (19). To determine the pathways enriched by latent viral 
infection, we used factorial analysis to determine the differentially expressed genes in each organ 
in WT MHV68 infected mice compared to mock mice and then removed any genes that were 
also differentially expressed in ORF73.stop-infected mice. The number of genes that were 
differentially expressed in both WT MHV68 and ORF73.stop-infected mice compared to mock 
was modest (65 for liver, 15 for spleen and 1 for brain). Of the 736 genes differentially expressed 
in the spleens of latently infected mice, we found that most genes were associated with cell cycle 
pathways (Fig. 4.3A). This is consistent with a previous report of differential gene expression in 
the spleens of mice infected with MHV68, the betaherpesvirus, murine cytomegalovirus 
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(MCMV), or the human alphaherpesvirus, herpes simplex virus (HSV) (26). In contrast, of the 
538 genes differentially expressed in the livers of latently infected mice, most differentially 
expressed genes were associated with immune signaling and immune response pathways, 
including interferon signaling (Fig. 4.3B). The immune-related gene expression changes detected 
in the liver were consistent with histological sections in which foci of inflammatory cells were 
visible from mice infected with WT MHV68, but not ORF73.stop virus or mock-infected mice, 
and likely reflected the immigration of inflammatory cells rather than changes in resident 
hepatocytes (data not shown). Because of the potential of diurnal gene regulation as a 
confounding factor and the fact that the circadian rhythm was identified as a significant pathway 
for differentially expressed genes in WT MHV68 livers when compared to livers from mock 
mice, we identified the circadian genes (Clock, Cpt1a, Elovl3, Per1 and Per2) that were 
differentially expressed in the livers of latently infected mice and repeated pathway analysis with 
these removed to test their effect on latency-specific pathways. The pathway of genes involved 
in platelet activation, signaling and aggregation was no longer statistically significant. The 
number of genes in the overlap with the pathway of genes involved in metabolism of lipids and 
lipoproteins decreased by three and the –log of the q-value decreased to 4.0915 from 5.9586. All 
of the other pathways were insensitive to the removal of the circadian clock genes. Although 
there were few genes whose expression changed in the brains of latently infected mice (32), 
many of the genes altered in the brain were also differentially expressed in the liver or spleen of 
latently infected mice (see Fig. 4.1). The pathways significantly enriched in brains of latently 
infected mice were predominantly related to the immune system and interferon signaling (Fig. 
4.3C). Finally, we tested what pathways were enriched across multiple tissues. We found that 
there were 109 genes that were differentially expressed in both livers and spleens of latently 
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infected mice. The immune system generally and interferon signaling specifically were the most 
significant pathways for these overlapping genes (data not shown). Taken together, these results 
demonstrate that latent viral infection differentially altered host gene expression specifically by 
tissue type, suggesting that there are distinct tissue responses to the host inflammatory response 
induced by chronic infection and that the modest number of common gene expression changes 
across tissues may be largely attributable to chronic interferon signaling (1). 
 
4.2.3 Differentially expressed genes are significantly associated with genes regulated by 
the cytokine, interferon gamma. 
IFNγ is required for controlling MHV68 reactivation from latency and persistent viral 
replication and is elevated in the serum of latently infected mice (1, 6, 18, 22). Previous work 
suggested that IFNγ is critical to latency-induced cross-protection to bacteria challenges and that 
CNS-infiltrating T cells in MHV68-exacerbated EAE produce elevated levels of IFNγ (1, 2). Our 
microarray pathway analysis also confirmed that the IFNγ pathway was one of the most 
significantly enriched pathways in livers and brains of latently infected mice. To confirm that 
host genes induced in the setting of chronic MHV68 infection are also regulated by IFNγ, we 
compared our list of differentially expressed genes in mice infected with WT MHV68 (relative to 
mock-infected mice) to a list of IFNγ-regulated genes in murine bone marrow-derived 
macrophages (10). We found that there was significant overlap between IFNγ-regulated genes in 
bone marrow-derived macrophages and tissues from MHV68-infected mice. Of the 359 genes 
regulated by IFNγ, 59 were regulated in the liver (p-value = 2.4390e-27), 72 were regulated in 
the spleens (p-value = 7.4127e-33) and 12 were regulated in the brain (p-value = 1.8151e-13) of 
latently infected mice (Fig. 4.4). Many of the most differentially expressed genes in all three 
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tissues from latently infected mice (Tables 4.2-4.4) are known to be induced by IFNγ, including 
Igtp, Iigp1, Gbps, Ccl5, Cxcl9, and MHC molecules. IFNγ itself was significantly upregulated in 
the spleens of latently infected mice (Fig. 4.2 and Table 4.2), an organ in which significantly 
reduced Listeria and Yersinia titers are observed in latently-infected animals, suggesting a 
mechanism by which latently-infected mice resist lethal bacterial challenges (1). Interestingly, 
the key IFNγ signaling molecule, Stat1, was one of the most upregulated genes in both livers and 
spleens of latently-infected mice (Tables 4.2-4.3). This suggests that active interferon signaling 
was also present in the livers of latently-infected mice where Listeria titers are reduced (1). 
These results suggest that many of the differentially expressed genes in latently infected mice 
were a result of elevated IFNγ levels in the host which have been detected during chronic 
MHV68 infection and are mechanistically important to latency-induced cross-protection (1). 
 EAE exacerbation by latent MHV68 is not only associated with IFNγ, but also with 
increased inflammatory infiltration into the CNS and elevated serum levels of chemokines, Ccl5 
and Cxcl9, which are known to attract T cells (2). Although the authors were unable to detect 
these chemokines in the CNS of latently infected mice, Ccl5 and Cxcl9 are significantly elevated 
in mouse sera from latently infected mice at the onset of EAE symptoms (2). Importantly, we 
detected Ccl5 and Cxcl9 as two of the most differentially expressed transcripts in the brains of 
latently infected mice (Table 4.4). These data suggest that elevated Ccl5 and Cxcl9 expression in 
the brain during latent infection may induce T cell migration into the CNS leading to augmented 
EAE symptoms. 
Activated macrophages have been implicated in several models of latency-induced cross-
protection, including challenges with bacteria and influenza virus (1, 16). Specifically, these 
models have identified activated macrophages as those expressing increased MHC class II 
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molecules. MHC class II molecules, specifically H2-Aa and H2-Eb1, were among the most 
highly differentially expressed genes in the livers and brains of latently-infected mice (Tables 
4.3-4.4). These data confirm that latent MHV68 infection can induce upregulation of MHC class 
II molecules in multiple organs with implications for cross-protection to a range of infectious 
challenges. 
Here, we show that infection with a chronic herpesvirus infection can profoundly alter 
gene expression in the host in a tissue-specific manner. The observed host transcriptional 
changes induced by latent infection were predominantly immune-related genes. However, the 
specific genes and pathways induced in latently infected animals differed by tissue type. Whether 
this was due to local differences in the inflammatory milieu or differential tissue responses to the 
same stimulus is unknown. However, given the differential effects of interferons and interferon-
regulated molecules in different cell types (3, 4, 8, 15, 20, 24), it is reasonable to hypothesize 
that the differences observed here were the result of differential cell responses and cell 
composition in specific organs. 
It is interesting to speculate what effects the gene expression changes induced by latent 
viral infection might have on the function of host tissues. Previous studies delineating a role for 
MHV68 in exacerbating EAE pathology (2, 14) in addition to the importance of IFNγ in EAE 
pathogenesis (9) and in the induction of many of the changes observed here, suggest that the 
gene expression changes induced in the setting of latent viral infection may alter the course of 
chronic disease pathogenesis. In a previous study of splenic gene expression changes in response 
to HSV, MCMV, or MHV68 infection, the authors identified virus-specific changes (26), 
suggesting that there may be important, dynamic and complex gene expression changes in a 
human host infected with multiple viruses. Taken together, these results demonstrate that chronic 
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viral infection can have profound and distinct effects on the host with potential implications for 
tissue function and pathogenesis of chronic disease in susceptible hosts. 
Microarray data have been deposited in GeoArchive, series number GSE51365. 
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Figure 4.1: Latent MHV68 alters host gene expression. Male C57Bl/6 mice were infected 
intranasally with MHV68, ORF73.stop mutant virus (ORF73) or mockulum (mock) and spleens, 
livers and brains (3 experiments) were harvested at 28 d.p.i. RNA was extracted using the 
ToTALLY RNA kit (Ambion) from tissues incubated in RNAlater-ICE (Ambion). Equal 
amounts of RNA were pooled from three to four mice per condition for each microarray chip. 
RNA was labeled and hybridized to Affymetrix M430 2.0 microarrays at the Multiplexed Gene 
Analysis Core Facility at Washington University in St. Louis. Data were normalized using 
Robust Multi-array Average normalization routine in Affymetrix’s Expression Console software. 
Microarray data were analyzed by both factorial analysis and two-way ANOVA. Differentially 
expressed genes identified by both analyses are shown in the heat map after hierarchical 
clustering of the genes. The heat map represents the fold change relative to mock-infected mice 
with red representing the row maximum and blue the row minimum value. Statistical 
significance was performed by standard student's t-test in the case of factorial analysis. P-values 
were corrected for multiple hypothesis testing. Gene expression differences were considered 
significant if the adjusted p-value < 0.05 and > 1.5-fold change was observed in expression 
levels. Mice were handled in accordance with federal and Washington University regulations. 
Figure generated by Dr. Gautam Goel
128 
 
 
Figure 4.2: Validation of microarray analyses by qRT-PCR. RNA pooled from three to four 
mice per condition was treated with TURBO DNase (Life Technologies) before cDNA synthesis 
using 1 ug RNA, oligo(dT)12-18 and Superscript II reverse transcriptase (Life Technologies). 
qPCR was performed on cDNA from livers (A) or spleens (B) using Power SYBR Green Master 
Mix (Applied Biosystems) with the indicated gene specific primers (Table 4.1). Data were 
collected from 4 independent experiments. Transcript levels were normalized to the level of 
GAPDH within each sample and compared to the level in mock-infected mice using the ΔΔCT 
method (where CT is the threshold cycle). Data are presented as mean ± S.E.M. Statistical 
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analyses were performed by Mann-Whitney U test. * p<0.05; ns = not significant; nd = could not 
reliably detect target. 
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Figure 4.3: Pathway analysis of differentially expressed genes in latently infected mice. 
Gene overlap analyses of differentially expressed genes in spleens (A), livers (B), or brains (C) 
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of MHV68-infected mice. A list of latent infection-specific differentially expressed genes was 
identified by comparing MHV68-infected mice to mock-infected mice and then removing genes 
that overlapped with those differentially expressed from ORF73.stop-infected mice compared to 
mock-infected mice. Pathways were identified using MSigDB's Canonical Pathway gene set. The 
50 most significant pathways for spleens (A) and livers (B) are displayed. The x-axis represents 
the q-value, indicating the significance of enrichment for a given gene set. The values are plotted 
on a negative log10 scale. Gene sets with values of > 1.3 (q-value < 0.05) were significantly 
enriched. Figure generated by Dr. Gautam Goel. 
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Figure 4.4: Overlap of genes regulated by IFNγ and latent viral infection. Heat map of 
differentially expressed genes in livers, spleens, or brains from MHV68-infected mice (compared 
to mock-infected mice) that significantly overlapped with genes altered by IFNγ in bone 
marrow-derived macrophages. The heat map displays the fold change relative to mock-infected 
mice with red representing the row maximum and blue the row minimum value. Statistical 
significance was assessed by a hypergeometric test. Nominal p-values were used. Figure 
generated by Dr. Gautam Goel.
134 
 
Table 4.1: Primers used in this study for qRT-PCR 
Target F primer R primer 
Batf TCAAGAAGGGGAGCCAGCTA GCAGCGATGCGATTCTTCTC 
Gbp1 AAGAAGTGAAGCAGGGGACA GCGGCTTCTGCTTTTATACG 
IFNγ CCTGCGGCCTAGCTCTGA TGGCAGTAACAGCCAGAAACAG 
Igtp CCTGTTTTAGCCCGTCTTTTCACG TCCTTCAGAGAGAACGCCTTATTGC 
Iigp1 CATTGAAAAGAAGCGGCAATTT CAGTGCGGTAGAATTTCATGCT 
Il18rap CAGATCATCTCACCGGCCTC AAACACCCAGCCCAAACAGA 
Marco TCATGGCCATCCACCTGATC GCCCACTGCAGCGAGAAGAA 
Plek TCCTGGATAGCCCTGATGCT TCACCCCCAGCAGGATCATA 
Syk GCCTTGCTAAGTGCGACATTG GGCTATGCAGCCTTTGTAGCTTT 
Vcam1 CTGGGAAGCTGGAACGAAGT GCCAAACACTTGACCGTGAC 
GAPDH TGCCCCCATGTTTGTGATG TGTGGTCATGAGCCCTTCC 
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Table 4.2: Genes most differentially expressed in spleens of latently-infected mice 
 
Gene ID Gene Name 
Signal to 
Noise 
Ratio 
Up or Down 
relative to 
ORF73.stop 
CXCL9  chemokine (C-X-C motif) ligand 9 22.9176 Up 
SAA3 serum amyloid A 3 14.5842 Up 
TTC39C  tetratricopeptide repeat domain 39C 10.3055 Up 
GBP1  guanylate binding protein 1, interferon-inducible 10.1534 Up 
IGTP  interferon gamma induced GTPase 10.0122 Up 
TIMP1  tissue inhibitor of metalloproteinase 1 9.8577 Up 
GZMB  granzyme B 8.3171 Up 
MELK  maternal embryonic leucine zipper kinase 7.8645 Up 
INCENP inner centromere protein 7.499 Up 
GPNMB  glycoprotein (transmembrane) nmb 7.1763 Up 
AA467197  expressed sequence AA467197 6.9617 Up 
OSBPL3  oxysterol binding protein-like 3 6.7681 Up 
MKI67 antigen identified by monoclonal antibody Ki 67 6.5786 Up 
FABP5 fatty acid binding protein 5, epidermal 6.5125 Up 
IFNG  interferon gamma 6.4947 Up 
RRM2   ribonucleotide reductase M2 5.999 Up 
MARCO  macrophage receptor with collagenous structure -5.7155 Down 
GBP2  guanylate binding protein 2 5.6835 Up 
2410003J06RIK  Mageb16 melanoma antigen family B, 16 5.6572 Up 
XDH  xanthine dehydrogenase 5.5757 Up 
STX3  syntaxin 3 5.2772 Up 
BHLHE40  basic helix-loop-helix family, member e40 5.2416 Up 
IL1RL1 interleukin 1 receptor-like 1 5.1771 Up 
CDC45L  cell division cycle 45 5.1685 Up 
TRAFD1 TRAF type zinc finger domain containing 1 5.126 Up 
TAP1  transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 5.1003 Up 
PARP9  poly (ADP-ribose) polymerase family, member 9 4.9727 Up 
CDC6  cell division cycle 6 4.9208 Up 
IIGP1  interferon inducible GTPase 1 4.9031 Up 
IRG1 immunoresponsive gene 1 4.8747 Up 
PDCD1  programmed cell death 1 4.8335 Up 
RACGAP1  Rac GTPase-activating protein 1 4.7826 Up 
HK2 hexokinase 2 4.766 Up 
CDKN1A  cyclin-dependent kinase inhibitor 1A (P21) 4.6531 Up 
KIF4  kinesin family member 4 4.6377 Up 
UBAC1  ubiquitin associated domain containing 1 4.6097 Up 
UPP1 uridine phosphorylase 1 4.5889 Up 
DTX1  deltex 1 homolog -4.5719 Down 
CLEC4D  C-type lectin domain family 4, member d 4.5384 Up 
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Table 4.3: Genes most differentially expressed in livers of latently-infected mice 
 
Gene ID Gene Name 
Signal to 
Noise 
Ratio 
Up or Down 
relative to 
ORF73.stop 
IGTP  interferon gamma induced GTPase 7.3767 Up 
MS4A4B  membrane-spanning 4-domains, subfamily A, member 4B 6.1604 Up 
IIGP1  interferon inducible GTPase 1 5.726 Up 
STAT1  signal transducer and activator of transcription 1 5.4494 Up 
PTPN18  protein tyrosine phosphatase, non-receptor type 18 5.4011 Up 
FYB  FYN binding protein 5.0647 Up 
H2-Q7  histocompatibility 2, Q region locus 7 5.013 Up 
LY6A  lymphocyte antigen 6 complex, locus A 4.7926 Up 
LCK  lymphocyte protein tyrosine kinase 4.7378 Up 
SAA3  serum amyloid A 3 4.6449 Up 
GZMK  granzyme K 4.6062 Up 
GZMA  granzyme A 4.2374 Up 
GPR65  G-protein coupled receptor 65 4.142 Up 
BC023105 cDNA sequence BC023105 4.0748 Up 
RGS1 regulator of G-protein signaling 1 4.0444 Up 
MPA2L  guanylate binding protein 6 4.022 Up 
LST1  leukocyte specific transcript 1 3.9534 Up 
SAMHD1  SAM domain and HD domain, 1 3.9515 Up 
S100A4  S100 calcium binding protein A4 3.9262 Up 
GBP8 guanylate-binding protein 8 3.8212 Up 
ZBP1  Z-DNA binding protein 1 3.8156 Up 
PITPNM1  phosphatidylinositol transfer protein, membrane-associated 1 3.752 Up 
FCGR4  Fc receptor, IgG, low affinity IV 3.678 Up 
TAP1  transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 3.5956 Up 
PTGER4  prostaglandin E receptor 4 (subtype EP4) 3.5583 Up 
CAR14  carbonic anhydrase 14 -3.4574 Down 
ADCY7  adenylate cyclase 7 3.4362 Up 
GBP2  guanylate binding protein 2 3.373 Up 
CCL5  chemokine (C-C motif) ligand 5 3.3726 Up 
H2-AA  histocompatibility 2, class II antigen A, alpha 3.3344 Up 
PSMB8  
proteasome (prosome, macropain) subunit, beta type 8 (large 
multifunctional peptidase 7) 3.2619 Up 
H2-K1  histocompatibility 2, K1, K region 3.2481 Up 
S100A6   S100 calcium binding protein A6 (calcyclin) 3.2016 Up 
EPB4.1L3   erythrocyte protein band 4.1-like 3 3.15 Up 
LAPTM5  lysosomal-associated protein transmembrane 5 3.1224 Up 
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Table 4.4: Genes most differentially expressed in brains of latently-infected mice 
 
 
Gene ID Gene Name 
Signal 
to 
Noise 
Ratio 
Up or Down 
relative to 
ORF73.stop 
IIGP1  interferon inducible GTPase 1 8.358 Up 
GBP2  guanylate binding protein 2 6.2147 Up 
H2-Q7  histocompatibility 2, Q region locus 7 5.3892 Up 
H2-K1  histocompatibility 2, K1, K region 4.5909 Up 
GBP6 guanylate binding protein 6 4.0888 Up 
CCL5  chemokine (C-C motif) ligand 5 3.6399 Up 
MS4A4B  membrane-spanning 4-domains, subfamily A, member 4B 3.2078 Up 
IGTP  interferon gamma induced GTPase 3.1533 Up 
H2-EB1  histocompatibility 2, class II antigen E beta 3.1481 Up 
MPA2L guanylate binding protein 6 2.5005 Up 
CXCL9  chemokine (C-X-C motif) ligand 9 2.4388 Up 
H2-AA  histocompatibility 2, class II antigen A, alpha 2.414 Up 
PSMB9  
proteasome (prosome, macropain) subunit, beta type 9 (large 
multifunctional peptidase 2) 1.9199 Up 
PLAC8  placenta-specific 8 0.9556 Up 
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5.1 Summary 
Herpesviruses can undergo both productive replication and the establishment of a latent 
infection. Understanding the role of viral genes in both stages of the viral life cycle and how the 
immune system works to control viral infection are areas of interest in the field. The unifying 
theme of this dissertation is investigation of gene expression and regulation during the course of 
gammaherpesvirus 68 infection. Many viral genes are expressed during productive infection; in 
fact, recent work by our laboratory and others has identified many new regions of active 
transcription outside of the known genes, suggesting that viral RNA expression during 
productive replication is more extensive than previously appreciated (5, 22). The function of 
such RNAs in MHV68 has not been investigated to date. During latent infection, few transcripts 
are produced. The regulation of viral gene expression to transition between productive 
replication and latency and the involvement of host factors, such as IFNs, in this process are 
areas of current investigation. Moreover, chronic MHV68 infection fundamentally alters the host 
response to a range of infectious and autoimmune challenges; an open question is what effect 
chronic immune stimulation has on host gene expression.  In this dissertation, I sought to address 
three questions: 
(1) Are transcripts from EGRs functionally important for viral gene expression during 
productive infection? 
(2) How does the cytokine IFNγ regulate productive infection of macraphages? 
(3) What is the effect of chronic viral infection on host gene expression? 
In Chapter 2, we used new mass sequencing approaches to confirm pervasive 
transcription by MHV68 and characterized several regions of complex, antisense transcription. 
We found that several novel EGR-encoded transcripts altered late gene expression and that 
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transcripts within EGRs 26 and 27 altered the expression of the lytic-switch gene encoded by 
ORF 50. These data suggest that these newly identified RNAs may play an important and 
previously unrecognized role in regulating viral gene expression. 
 In Chapter 3, we sought to understand the mechanism of cell extrinsic control of the virus 
by the host immune response in macrophages, specifically by IFNs. We have defined a role for 
IFNγ and its key signaling molecule, Stat1, in regulating transcript expression and promoter 
activity of the latent-to-lytic switch gene, RTA, encoded by ORF 50. Stat1 is also a key signaling 
molecule for type I IFNs, and Stat1-deficiency in the absence of IFNγ also increased viral 
replication, ORF 50 expression, and ORF 50 promoter activity, suggesting a role for type I IFNs 
in regulating ORF 50 expression in macrophages. Together, these results suggest that MHV68 
has evolved to regulate viral gene expression at least in part based on cell extrinsic signals, 
specifically IFNs. 
 In Chapter 4, we investigated the effect of latent viral infection on host gene expression 
in latently infected mice. We found that many genes were differentially expressed in the livers, 
spleens and brains of latently infected mice compared to uninfected mice or mice infected with a 
latency-defective virus. Many of the pathways of the genes differentially expressed genes in 
latent mice are immune-related pathways and specifically IFN signaling pathways. Interestingly, 
we observed distinct transcriptional signatures in livers and spleens of latently infected mice; in 
fact, many of the differentially expressed genes in spleens were in cell cycle pathways. Together, 
these results suggest that the immune system in a latently infected host is profoundly different 
from that of an uninfected host or one that has cleared an acute infection. These findings further 
support the proposed immune-mediated mechanisms of latency-induced phenotypes (such as the 
important role of activated macrophages in protection against bacterial or influenza virus 
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infection (1, 38)) and have implications for understanding the complexity of the immune 
responses in latently infected hosts. 
 
5.2 Function of products of pervasive transcription in MHV68 
 We and others identified extensive pervasive transcription in MHV68 (Chapter 2 and (5, 
22)). In this dissertation, I investigated the function of EGR-encoded transcripts outside of 
known ORFs and found evidence that transcripts encoded by EGRs alter viral gene expression, 
suggesting a role for these transcripts during productive infection in vitro. 
There are many remaining avenues of future investigation for this topic, including: (1) 
identification and functional characterization of other transcripts encoded by EGR 27 and EGR 
26; (2) examination of the transcriptional architecture of other EGRs and characterization of 
encoded transcripts; and (3) testing the role of EGR-encoded transcripts during acute and chronic 
infection in vivo. Moreover, it will be interesting to investigate the function of similar transcripts 
in other herpesviruses. Our results suggest that pervasive transcription described in KSHV and 
HCMV (4, 11, 53, 54) and likely present in other human herpesviruses may well have important 
functions in viral replication and viral pathogenesis. 
 
5.2.1 Further functional analysis of EGR 26 and EGR 27 transcripts 
To date, we have found that ASOs targeting EGRs 26 and 27 alter viral gene expression. 
However, there are some questions still to be resolved such as why EGR 26a-c ASOs, but not 
EGR 26d-e ASOs, reduce ORF 6 transcript levels (Chapter 2). These data suggest that the effects 
that we have described for EGR 26a-c ASOs were the result of targeting a smaller transcript or 
spliced isoform within EGR 26. Left unexplored by our work to date is the significance of the 
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additional 3' ends detected by RNA sequencing within EGR 27 and ORFs 66-67 which may 
correspond to additional, less abundant EGR 27 transcripts. In addition, I have performed 3' 
RACE in the EGR 27 region that further suggests the presence of multiple RNAs within EGR 27 
that are less abundant than EGR 27 transcripts A and B (data not shown). Analysis of our RNA 
sequencing data by Dr. Steve Johnson suggests splicing is common throughout the virus, 
especially in EGRs 23, 26 and 27 (unpublished observations). The fact that EGR 27d ASO 
reduced levels of EGR 27 transcript B and exerted the same effect on ORF 6 and ORF 50 
transcript levels as EGR 27a ASO suggests that transcription in this region may be even more 
complex than depicted in Chapter 2 and suggests that there may be an additional transcript 
encoded by EGR 27 or a spliced isoform that is functionally important. Additional detailed 
mapping of the transcripts in this region would help to further elucidate the complex 
transcriptional architecture in this region. Together, these data suggest that the northern blot 
analysis and transcriptional mapping to date may not completely capture the complexity of the 
MHV68 transcriptome. 
It is worthwhile considering the implications for analysis of mammalian transcriptomes 
with our data in mind. We were able to achieve a great depth of sequencing coverage given the 
small size of the MHV68 genome relative to a mammalian genome. Analysis of the human 
transcriptome has revealed similar complex and pervasive transcription across the genome (6, 
18). Some of these transcripts have only been detected with a single read (18), suggesting that 
the current sequencing depth may only scratch the surface of the complexity of the mammalian 
transcriptome. 
 As described in Chapter 2, we have identified transcripts emanating from EGRs 26 and 
27 that overlap the capsid protein, M9 (ORF 65) (3, 31). Previous studies have shown that the 
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M9 region plays a number of divergent roles in the MHV68 life cycle, including a candidate 
region of latent gene expression and a component of the virion (19, 34, 48). It is intriguing to 
consider whether transcripts encoded by EGRs 26-27 may be produced during latency. 
Determining whether EGR 26-27 transcripts or other EGR-derived transcripts are produced 
during latency would be an interesting area for future research. However, it is also possible that 
the detection of the M9 region in latently infected cells is the result of low level reactivation 
events from a highly expressed region of the virus. 
 Our data suggest that transcripts encoded by EGRs 26 and 27 regulate ORF 50 expression 
since ORF 50 transcript levels are decreased in cells transfected with EGR 27a, 27d or 26c ASOs 
(Chapter 2). This has important implications for regulation of viral replication given the central 
role of ORF 50 in viral gene expression. Defining the precise transcripts encoded by EGRs 26 
and 27 that modulate ORF 50 expression is an important next step. Additionally, understanding 
how such transcripts regulate ORF 50 expression is a critical topic for future investigation. It is 
intriguing to speculate whether EGR 26 or 27 transcripts regulate ORF 50 expression by acting 
as a molecular scaffold for chromatin-modifying complexes like KSHV PAN RNA or might 
sequester proteins that act to repress ORF 50 promoter activity (35). One avenue to investigate 
the role of chromatin proteins and EGR-derived transcripts would be to use RNA 
immunoprecipitation, in which RNA binding proteins are immunoprecipitated, in combination 
with RNA sequencing (RIP-Seq) to identify RNA-protein interactions. For example, it would be 
interesting to determine whether the HDAC3/4/NCoR complex known to repress ORF 50 
promoter activity interacts with EGR-encoded transcripts (14). Although activating complexes or 
modifications of ORF 50 promoters are less well-characterized at present, several recent studies 
have identified activating histone modifications in KSHV (15, 45). Such studies in MHV68 
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could lead to candidate proteins that interact with ORF 50 promoters and EGR-encoded 
transcripts. Additional discussion on ORF 50 regulation by EGR-encoded transcripts is included 
in the section on ORF 50 regulation below 
 Our data suggest that EGR 27 transcript A may act later in the viral life cycle than EGR 
27 transcript B and therefore may have a distinct function. Further work will be needed to clarify 
the role of EGR 27 transcript A including targeting this transcript with additional ASOs. The 
second ASO that we designed to this region reduced the abundance of EGR 27 transcript B in 
addition to the levels of EGR 27 transcript A even though it was not predicted to target the 
former. The one ASO that specifically targeted EGR 27 transcript A (EGR 27c ASO) reduced 
late gene expression as well as protein levels of the early gene, ORF 6, but not ORF 6 transcript 
levels or ORF 50 transcript levels. The lack of an effect on the immediate-early gene, ORF 50, 
suggests that this RNA acts later in the viral life cycle than EGR 27 transcript B and may play a 
role in viral protein expression or viral DNA replication, rather than a role in regulating viral 
transcription. Interestingly, a role in viral DNA replication has been described for the EBV 
BHLF1 transcript, which forms an RNA-DNA hybrid molecule at the origin of lytic replication 
(OriLyt) and is important for recruitment of the viral single stranded binding protein, BALF2, to 
OriLyt (33). 
 Importantly, while our data demonstrate that RNAs derived from EGRs are functionally 
important for the virus, our strategy has been limited to transient knockdown with single-
stranded ASOs. As is to be expected with such a strategy, we observed partial transcript 
knockdown and as a result, subtle phenotypes. Several options are available for further study of 
EGR-encoded transcripts, including transfecting cells with multiple ASOs targeting the same 
transcript or the generation of a knockout virus. Again, given the transcriptional complexity of 
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MHV68, such a strategy necessitates thorough transcript mapping. Given the complex nature of 
MHV68 transcription with multiple overlapping and antisense transcripts, the feasibility of 
making a knockout virus will depend on the precise transcriptional architecture of the region of 
interest. Future work could also utilize overexpression of transcripts of interest to confirm the 
phenotypes reported here and to investigate the function(s) of other EGR-encoded transcripts. It 
will be important, however, to consider the contribution of antisense transcripts of known ORFs 
in any such experiments. For example, EGR 26 transcript A encompasses the entire transcript 
and putative promoter for ORF 64 as well as most of ORF 63. One option would be to mutate the 
sequence for the antisense ORF so that overexpression findings are not confounded by it. 
 
5.2.2 Transcriptional architecture and functional analysis of other EGR-encoded 
transcripts 
 The work in this dissertation has primarily focused on EGRs 26 and 27 as targeting of 
transcripts encoded by these EGRs had the greatest effect on ORF 4 surface expression, making 
them the best candidates for mechanistic studies with the available reagents. However, it is clear 
from our ORF 4 flow cytometry screen that other EGR-encoded transcripts may function in viral 
gene expression (Chapter 2). Moreover, there are sixteen EGRs that we did not target in our 
screen and have not been investigated by any means; these EGRs could form the basis of 
additional screens. 
 One region of particular interest is EGR 23, which is antisense to ORF 50. A transcript in 
KSHV has also been described from a sytenically-conserved region of the KSHV genome, 
though this RNA was found not to alter KSHV ORF 50 transcript levels and instead was 
proposed to encode small peptides (53). In MHV68, we have performed northern blot analysis of 
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EGR 23. A northern blot probe detected at least five overlapping polyadenylated transcripts 
between nucleotides 68313 and 68765 (Fig. 5.1). Additionally, Dr. Steve Johnson identified 
many splicing events by computational analysis of RNA sequencing data, confirming the 
presence of multiple overlapping transcripts in this region. The northern probe encompassed the 
targets of EGR 23a and 23b ASOs which significantly reduced ORF 4 surface expression 
(Chapter 2). Mapping transcripts encoded by EGR 23 and determining the role of each in viral 
gene expression is an area of interest for future research and could be achieved using similar 
methods to those used for analyzing transcripts derived from EGRs 26 and 27. Preliminary 
western blot analysis suggests that, unlike transcripts encoded by EGRs 26 and 27, transcripts 
targeted by EGR 23b ASO did not reduce protein levels of the early gene, ORF 6 (data not 
shown). An effect specifically on late genes suggests a role for EGR 23 transcripts in viral DNA 
replication and suggests that distinct EGR-encoded transcripts function in different stages of the 
viral life cycle. 
 Two of the ASOs used in our ORF 4 flow cytometry screen increased ORF 4 surface 
expression suggesting that the targeted RNAs may have a role in suppressing viral gene 
expression (Chapter 2). It will be interesting to overexpress these RNAs and confirm that these 
RNAs act to restrict viral gene expression and to further assess the role of these RNAs in vivo. It 
is intriguing to hypothesize that RNAs that suppress viral gene expression in vitro may play a 
role in establishing or maintaining latency. 
Finally, while EGR 26-27 transcripts are enriched in the nucleus of infected cells, 
suggesting that they are nuclear noncoding RNAs, the localization of other EGR-encoded 
transcripts have not been evaluated thus far. If other EGR-encoded transcripts were found to be 
expressed in the cytoplasm, these RNAs may be cytoplasmic ncRNAs or may encode peptides or 
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small proteins. In addition to determining nuclear versus cytoplasmic localization for other EGR-
encoded transcripts, the best option for evaluating which RNAs might encode proteins or 
peptides would be ribosomal profiling. In ribosomal profiling, RNAs associated with ribosomes 
are isolated using a sucrose gradient and then sequenced to determine their identity. A recent 
report has defined a pattern of ribosome release that is characteristic of ncRNAs (17). Using a 
combination of subcellular fractionation and ribosome profiling, it will be interesting to 
determine which EGR-encoded transcripts are likely to be noncoding and which might be 
translated. 
 
5.2.3 Role of EGR-encoded transcripts during infection in vivo 
 An advantage of studying MHV68 is the opportunity to investigate the role of viral and 
host genes in the context of in vivo infection. Studies to date of herpesvirus ncRNA have 
necessarily focused on the effect of such RNAs in vitro (Chapter 2 and (2, 8, 20, 21, 23, 24, 28, 
30, 35-37, 39-41)). Depending on the transcriptional architecture of the specific EGR-encoded 
transcript in question, it may be possible to generate a mutant virus and then to use this virus to 
infect mice. Infection of mice with a mutant virus would allow us to determine the role of a 
specific RNA in acute viral infection, establishment of and reactivation from latency, and the 
production of persistent virus as well as virus-induced pathologies, such as large-vessel vasculitis 
and the development of lymphoma. Because of the evident transcriptional complexity in many 
regions, an alternative is to generating a mutant virus is to target a specific EGR-encoded 
transcript in vivo using ASOs shown to knockdown the transcript of interest in vitro (Chapter 2 
and (16, 49, 50)). 
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Finally, for RNAs hypothesized to play a role in modulating the host response to 
infection, it may be possible to deliver such RNAs individually and investigate their role in the 
host immune response outside of the context of viral infection. As an example, an RNA could be 
overexpressed in vitro and the effect on host gene expression evaluated by microarray or RNA 
sequencing. If such an RNA substantially altered a host pathway, such as IFN signaling, this 
would indicate that it may have a role in modulating the host response to infection and would be 
a candidate for evaluation in vivo. This could be accomplished by generating a transgenic mouse 
as has been done for the mammalian ncRNA, NeST (13). 
 
5.3 Stat1 regulation of gammaherpesvirus 68 ORF 50 
transcription 
 In this dissertation, I have presented evidence that ORF 50 promoters are regulated by the 
host cytokine, IFNγ, and its key signaling molecule, Stat1, and that type I IFNs may also regulate 
ORF 50 promoters via an IFNγ-independent role of Stat1. Preliminary chromatin 
immunopreciptation (ChIP) experiments by Dr. Megan Goodwin suggest that Stat1 does not bind 
directly to the ORF 50 promoters in the presence or absence of IFNγ (data not shown), 
suggesting that Stat1-mediated repression is indirect. Whether Stat1 sequesters activating 
complexes as it does to regulate MMP-9 (26) or acts indirectly via another transcription factor is 
unknown and could form the basis for future studies. There are several possible approaches to 
investigate the role of Stat1 in regulating ORF 50 promoters in the presence or absence of IFNγ. 
The best approach would be to screen for proteins that regulate ORF 50 promoter activity using a 
cDNA overexpression or siRNA knockdown library. Once additional transcriptional factors are 
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identified by such a screening approach, it would be possible to assess whether these factors bind 
directly to the ORF 50 promoters by ChIP. Another possibility is to analyze the ORF 50 
promoters for putative transcription factor binding sites and then assessing the role of candidate 
transcription factors in regulating ORF 50 promoters. Using MatInspector for analysis of the core 
and distal ORF 50 promoters (data not shown), we have identified many candidate binding 
elements, but as was shown for Stat1, many of these elements may not bind their predicted 
binding elements. Candidate proteins will need to be each tested empirically. Moreover, given 
that the mechanisms of IFNγ-mediated gene repression are less well-studied, we favor a screen 
over a candidate-based approach to better capture novel means of regulation. 
Type I IFN regulation of viral replication in macrophages is mediated by IRF3 (52). Type 
I IFN treatment of bone macrophages has been shown to directly reduce ORF 50 transcript 
levels, but the effect of type I IFN on ORF 50 promoter activity has not been formally tested to 
date and is an important next step (52). Further, it will be important to specifically test whether 
IRF3 mediates type I IFN control of ORF 50 promoter activity (52). Whether IRF3 binds directly 
to the ORF 50 promoters is unknown and could be tested by ChIP. If IRF3 does not bind 
directly, the screening described above can be used to identify additional candidate molecules for 
both type I and type II IFN regulation of ORF 50. 
It would be interesting to evaluate the role of IFN-repressible elements within the ORF 
50 promoters in the context of viral infection. We hypothesize that mutation of IFNγ-induced 
regulatory elements would generate a virus that persists and is insensitive to IFNγ regulation, 
reactivating even in the presence of an intact immune response, perhaps generating pathologies 
such as large-vessel vasculitis and lymphoma typically only observed in immunodeficient hosts 
(7, 25, 43, 44, 47). However, a complication to generating such a virus is that the Speck 
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laboratory has recently identified two additional ORF 50 promoters in addition to the two ORF 
50 promoters described here and has confirmed that these promoters are also responsive to IFNγ 
(personal communication). Moreover, the role of type I IFNs in regulating these novel promoters 
has not been evaluated to date. It is clear that the regulation of transcription of this key viral 
molecule is complex. 
 Another area for future investigation is to evaluate whether type I or type II IFNs interact 
with other regulators of ORF 50. One area of interest is determining whether IFNs regulate 
transcripts that overlap EGRs 26-27. Drs. Erin Willert and Steve Johnson investigated the role of 
IFNγ on viral gene expression by tiled array and found that nearly all viral genes, aside from 
ORF 73, were silenced by treatment with this cytokine (personal communication). Given the 
importance of ORF 50 in regulating viral gene expression, it is likely that many genes were 
suppressed due to decreased ORF 50 levels. However, in light of our data that EGR-encoded 
transcripts may regulate ORF 50 transcript expression (Chapter 2), it will be interesting to 
evaluate the effect of type I and type II cytokines on the promoters of EGR 26 and 27 transcripts. 
Furthermore, it is intriguing to speculate whether IFNγ, EGR 26 and 27-encoded transcripts, and 
the HDAC3/4/NCoR complex interact to regulate ORF 50 expression. This could be tested by 
RIP. Finally, in view of the role of KSHV PAN RNA in regulating ORF 50 gene expression, it 
will be interesting to test whether cytokines regulate the promoter of PAN RNA (35, 36). 
 Finally, other cytokines are known to be important in MHV68 infection. Like IFNγ, 
TNFα is upregulated during latent infection (1). However, the role of this cytokine in regulating 
ORF 50 promoter activity or MHV68 viral gene expression has not been evaluated. Moreover, 
recent research in our laboratory has uncovered a role for the TH2 cytokines, IL-4 and IL-13, in 
promoting viral replication in macrophages and ORF 50 promoter activity (Tiffany Reese, 
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personal communication). It will be interesting to define the mechanism of such cytokines on the 
ORF 50 promoters and viral gene expression. 
 
5.4 Latent infection alters host transcription 
 Previous work has defined a role for cells of the innate immune system, specifically 
macrophages and natural killer cells, in latency-induced phenotypes, including resistance to 
lethal challenges with bacterial pathogens, influenza virus, and lymphoma cells (1, 38, 51). We 
have now uncovered immune signatures in the brains, livers and spleens of latently infected 
MHV68. Interesting questions for future research include: (1) Are latency-specific host gene 
expression changes and latency-induced phenotypes, such as cross-protection to Listeria 
monocytogenes (1), attributable to establishment of latency or depend on the capacity to 
reactivate? (2) What are the latency-specific gene expression changes in specific cell types (e.g. 
macrophages) or other tissues (e.g. lung)? and (3) What is the effect of such transcriptional 
changes on cells of the adaptive immune system, specifically T cells? 
 
5.4.1 Relative contribution of latency establishment versus reactivation to latency-
induced phenotypes 
 Our work and the work of others have identified a role for latency in several latency-
induced phenotypes by comparing wild-type infection to infection with latency-defective 
MHV68 (Chapter 4 and (1, 9)). As a next step, it will be interesting to determine whether the 
capacity of the virus to reactivate influences latency-induced phenotypes. For example, we could 
compare infection of mice with ORF73.stop mutant virus to a virus such as ORF72.stop mutant 
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virus and then evaluate gene expression changes and resistance to lethal challenges with Listeria 
monocytogenes and influenza virus. The ORF72.stop mutant virus is able to establish a latent 
infection, but is profoundly defective in its ability to reactivate from latency whereas, when 
administered intranasally, the ORF73.stop mutant virus fails to establish a latent infection (10, 
29, 46). A crucial first experiment will be to test establishment of latency by limiting dilution 
PCR and ex vivo reactivation from latency by limiting dilution assay for mice infected with 
ORF72.stop mutant virus delivered intranasally to confirm that ORF72.stop mutant virus 
establishes latency, but is defective in reactivation from latency. Previous studies have 
demonstrated that the route of infection (intranasal vs. intraperitoneal) alters whether 
ORF73.stop mutant virus can establish a latent infection (29, 32). 
 
5.4.2 Effect of MHV68 latency on specific cell types and tissues 
 We have reported here distinct gene expression profiles for three specific tissues (brain, 
liver and spleen) from latently infected mice. It may be worthwhile to determine the gene 
expression profile of other tissues as well. Tissues of interest include the lung given the observed 
latency-induced protection to influenza virus infection (38). One limitation of our study was that 
we determined the gene expression profile for an entire organ, composed of multiple distinct cell 
types. Since macrophages are important in several models of latency-induced cross protection (1, 
38), it will be interesting to determine macrophage gene expression signatures from various 
tissues during latent infection. A recent comprehensive study has characterized macrophage-
specific markers and these could be used to isolate macrophages from tissues of interest (12). 
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5.4.3 Effect of latent infection on T cells 
During latent MHV68 infection, several cytokines, including type I and type II IFNs and 
TNFα, are produced (1, 27). A number of studies have suggested that the presence of cytokines, 
including IL-12 and type I IFNs, can alter effector T cell differentiation and responses (reviewed 
in (42)). Interestingly, there is a prominent type I IFN gene signature in bystander CD8+ memory 
T cells from mice chronically infected with lymphocytic choriomeningitis virus (LCMV), and 
this gene expression signature significantly overlaps with our signature from latently-infected 
mice (Erietta Stelekati and E. John Wherry, personal communication), suggesting that type I 
IFNs may play an important role in shaping bystander T cell responses during MHV68 latency as 
well. While type II IFN is unlikely to play a role in T cell conditioning, it may play some role in 
mediating B cell responses. In fact, antibody has been identified as required in a mouse model of 
MHV68-induced thrombocytopenia (9). 
 To directly test whether latent MHV68 infection altered T cells, we transferred naïve 
OT1 T cells into congenic mice prior to infection with wild type MHV68 or ORF73.stop mutant 
virus and assessed the transcriptional profile of the transferred cells by microarray analysis at 28 
days post infection. In a pilot experiment, we found that there were a number of differentially 
expressed genes between latently infected mice and mice infected with the ORF73.stop mutant 
virus (data not shown) suggesting that chronic viral infection altered CD8 T cells. One limitation 
of this experiment was that only a small percentage of the transferred T cells remained after five 
weeks. An alternative approach would be to transfer T cells after latency is established so that 
the cells would not need to survive as long in vivo before analysis. In addition to investigating 
the role of latent MHV68 on naïve bystander CD8+ T cells, it would be interesting to evaluate its 
role on naïve CD4+ T cells as well as effector and memory cells. If a distinctive gene signature is 
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confirmed in bystander T cells, it would be interesting to evaluate whether other herpesvirus 
infections, such as MCMV, have similar or distinct effects on T cell gene signatures. Whether 
type I IFN plays a critical role in the observed phenotypes could be evaluated by using IFNAR-/- 
transgenic T cells as bystander cells. Experiments such as these have implications for 
understanding how chronic viral infection may shape the mature immune response in humans. 
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Figure 5.1: Multiple polyadenylated transcripts emanate from EGR 23. 200 ng of poly(A)-
selected or 5 µg of total RNA isolated from MHV68-infected 3T12 fibroblasts (MOI=10) at 18 
hpi was analyzed by northern blot analysis using a probe to EGR 23 (nucleotides 68313 and 
68765). 
 
 
